0001493152-18-012269.txt : 20180820 0001493152-18-012269.hdr.sgml : 20180820 20180820061627 ACCESSION NUMBER: 0001493152-18-012269 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20180630 FILED AS OF DATE: 20180820 DATE AS OF CHANGE: 20180820 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VIVOS INC CENTRAL INDEX KEY: 0001449349 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 800138937 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53497 FILM NUMBER: 181027005 BUSINESS ADDRESS: STREET 1: 719 JADWIN AVENUE CITY: RICHLAND STATE: WA ZIP: 99352 BUSINESS PHONE: 509-736-4000 MAIL ADDRESS: STREET 1: 719 JADWIN AVENUE CITY: RICHLAND STATE: WA ZIP: 99352 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED MEDICAL ISOTOPE Corp DATE OF NAME CHANGE: 20081103 10-Q 1 form10-q.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

Form 10-Q

 

(Mark One)

 

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE QUARTERLY PERIOD ENDED: June 30, 2018

 

OR

 

[  ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE TRANSITION PERIOD FROM __________ TO __________

 

COMMISSION FILE NUMBER 000-53497

 

VIVOS INC

(Exact name of registrant as specified in its charter)

 

Delaware   80-0138937

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification No.)

 

719 Jadwin Avenue,

Richland, WA 99352

(Address of principal executive offices, Zip Code)

 

(509) 736-4000

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

 

  Large accelerated filer [  ]   Accelerated filer [  ]  
         
  Non-accelerated filer [  ]   Smaller reporting company [X]  
  (Do not check if a smaller reporting company)      
      Emerging growth company [  ]  

 

If an emerging growth company, indicate by check mark if the company has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [X]

 

As of August 16, 2018, there were 373,927,406 shares of the registrant’s Common outstanding and 2,770,940 shares of the registrant’s Series A Convertible Preferred Stock outstanding.

 

 

 

   
 

 

TABLE OF CONTENTS

 

    Page
  PART I – FINANCIAL INFORMATION  
     
Item 1. Condensed Financial Statements 1
     
  Condensed Balance Sheets as of June 30, 2018 (unaudited) and December 31, 2017 1
     
  Condensed Statements of Operations for the Three Months and the six months ended June 30, 2018 (unaudited) and the Three Months and the six months ended June 30, 2017 (unaudited) 2
     
  Condensed Statements of Cash Flow for the Six Months ended June 30, 2018 (unaudited) and the Six Months ended June 30, 2017 (unaudited) 3
     
  Notes to Condensed Financial Statements (unaudited) 4
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 11
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 19
     
Item 4. Controls and Procedures 19
     
  PART II – OTHER INFORMATION  
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 20
     
Item 6. Exhibits 20
     
SIGNATURES 21

 

 -i- 

 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

Vivos Inc.

Condensed Balance Sheets

 

   June 30,
2018		   December 31,
2017		 
   (unaudited)   (audited) 
ASSETS          
           
Current assets:          
Cash  $-   $8,317 
Prepaid expenses   7,492    6,711 
Total current assets   7,492    15,028 
           
Fixed assets, net of accumulated depreciation   -    - 
           
Other assets:          
Deposits   669    669 
Total other assets   669    669 
           
Total assets  $8,161   $15,697 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)          
           
Current liabilities:          
Accounts payable and accrued expenses  $1,040,275   $840,972 
Related party payables   82,572    57,297 
Accrued interest payable   480,436    347,069 
Payroll liabilities payable   216,436    85,786 
Derivative liability   5,232,274    - 
Convertible notes payable, net   3,158,807    2,563,272 
Loan from shareholder   50,000    - 
Notes payable   32,279    - 
Related party promissory note   383,771    383,771 
Total current liabilities   10,676,850    4,278,167 
           
Total liabilities   10,676,850    4,278,167 
           
Commitments and contingencies   -    - 
           
Stockholders’ equity (deficit):          
Preferred stock, $.001 par value, 20,000,000 shares authorized; 2,811,955 and 3,778,622 shares issued and outstanding, respectively   2,811    3,779 
Paid in capital, preferred stock   9,575,805    13,547,780 
Common stock, $.001 par value; 2,000,000,000 shares authorized; 117,757,943 and 65,695,213 shares issued and outstanding, respectively   117,758    65,695 
Paid in capital   50,836,259    46,408,443 
Accumulated deficit   (71,201,322)   (64,288,167)
Total stockholders’ equity (deficit)   (10,668,689)   (4,262,470)
           
Total liabilities and stockholders’ equity (deficit)  $8,161   $15,697 

 

The accompanying notes are an integral part of these condensed financial statements.

 

 -1- 

 

Vivos Inc.

Condensed Statements of Operations

(unaudited)

 

   Three Months Ended June 30,   Six Months Ended June 30, 
   2018   2017   2018   2017 
                 
Revenues  $-   $-   $-   $4,054 
                     
Operating expenses                    
Sales and marketing expenses   2,950    15,251    12,950    41,249 
Depreciation and amortization   -    733    -    1,473 
Professional fees   145,220    295,544    215,278    430,148 
Reserved stock units granted   32,801    -    84,895    - 
Stock options granted   21,645    27,059    45,400    55,299 
Payroll expenses   82,200    181,494    161,070    286,275 
Research and development   41,766    80,523    74,580    113,409 
General and administrative expenses   15,318    18,567    34,421    60,087 
Total operating expenses   341,900    619,171    628,594    987,940 
                     
Operating loss   (341,900)   (619,171)   (628,594)   (983,886)
                     
Non-operating income (expense)                    
Interest expense   (4,934,066)   (781,139)   (5,566,140)   (1,309,090)
Net gain on sale of assets   -    -    -    2,800 
Grants received   -    -    17,583    - 
Net gain (loss) on debt extinguishment   131,604    (201,574)   131,604    (53,863)
Gain (loss) on derivative liability   (867,608)   83,089    (867,608)   408,479 
Non-operating income (expense), net   (5,670,070)   (899,624)   (6,284,561)   (951,674)
                     
Income (Loss) before Income Taxes   (6,011,970)   (1,518,795)   (6,913,155)   (1,935,560)
                     
Income Tax Provision   -    -    -    - 
                     
Net Income (Loss)  $(6,011,970)  $(1,518,795)  $(6,913,155)  $(1,935,560)
                     
Basic and Diluted Income (Loss) per Common Share  $(0.0681)  $(0.0327)  $(0.0836)  $(0.0457)
                     

Basic and Diluted Weighted average common shares outstanding

   88,308,304    46,454,069    78,103,383    42,375,108 

 

The accompanying notes are an integral part of these condensed financial statements.

 

 -2- 

 

Vivos Inc.

Condensed Statements of Cash Flow

(Unaudited)

 

   Six months ended June 30, 
   2018   2017 
CASH FLOW FROM OPERATING ACTIVITIES:          
Net Loss  $(6,913,155)  $(1,935,560)
           
Adjustments to reconcile net loss to net cash used by operating activities:          
Depreciation of fixed assets   -    1,473 
Amortization of convertible debt discount   791,938    957,499 
Gain on sale of assets   -    (2,800)
Common stock issued for services   449    171,090 
Stock options and warrants issued for services   45,400    55,299 
Reserved stock units issued for services   84,895    - 
New derivatives recorded as loan fees   4,636,517    - 

(Gain) loss on derivative liability

   867,608    (408,479)
(Gain) loss on settlement of debt   (131,604)   53,863 
Changes in operating assets and liabilities:          
Prepaid expenses   (781)   5,142 
Accounts payable   266,795    39,949 
Accounts payable from related parties   (13,284)   (4,675)
Payroll liabilities   130,650    (60,212)
Accrued interest   137,696    350,468 
Net cash used by operating activities   (96,876)   (776,944)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
Sale of fixed assets   -    2,800 
Net cash from investing activities   -    2,800 
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Payments made for loan fees   -    (101,631)
Proceeds from shareholder advances   50,000    137,000 
Proceeds from related party advances   38,559    - 
Proceeds from convertible debt   -    1,080,334 
Net cash provided by financing activities   88,559    1,115,703 
           
Net increase (decrease) in cash   (8,317)   341,560 
Cash, beginning of period   8,317    27,889 
           
CASH, END OF PERIOD  $-   $369,449 
           
Supplemental disclosures of cash flow information:          
Cash paid for interest  $-   $- 
Cash paid for income taxes  $-   $- 

 

The accompanying notes are an integral part of these condensed financial statements.

 

 -3- 

 

Vivos Inc.

Notes to Condensed Financial Statements

(Unaudited)

 

NOTE 1: BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

 

The accompanying condensed financial statements of Vivos Inc. (the “Company”) have been prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and disclosures required by accounting principles generally accepted in the United States have been condensed or omitted pursuant to such rules and regulations. These condensed financial statements reflect all adjustments that, in the opinion of management, are necessary to present fairly the results of operations of the Company for the period presented. The results of operations for the six months ended June 30, 2018, are not necessarily indicative of the results that may be expected for any future period or the fiscal year ending December 31, 2018 and should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on April 2, 2018.

 

In April of 2017, the Company filed a Certificate of Merger with the Delaware Division of Corporations in order to merge the Company’s wholly-owned subsidiary, IsoPet Solutions Corporation, with and into the Company. The Company therefore no longer prepares Consolidated Financial Statements.

 

Use of Estimates

 

The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Fair Value of Financial Instruments

 

Fair Value of Financial Instruments, requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of June 30, 2018 and December 31, 2017, the balances reported for cash, prepaid expenses, accounts payable, and accrued expenses, approximate the fair value because of their short maturities.

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:

 

Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;

 

Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

 

Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

The Company measures certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis were calculated using the Black-Scholes pricing model and are as follows at June 30, 2018:

 

June 30, 2018                
                 
   Total   Level 1   Level 2   Level 3 
Liabilities:                    
Derivative Liability  $5,232,274   $    $    $5,232,274
Total Liabilities Measured at Fair Value  $5,232,274   $-   $-   $5,232,274 

 

 -4- 

 

Derivative Liabilities

 

The Company evaluates its convertible debt, options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with Accounting Standards Codification topic 815, Accounting for Derivative Instruments and Hedging Activities (“ASC 815”) as well as related interpretations of this standard and Accounting Standards Update 2017-11, which was adopted by the Company effective January 1, 2018. In accordance with this standard, derivative instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair values with gains or losses recognized in earnings. Embedded derivatives that are not clearly and closely related to the host contract are bifurcated and are recognized at fair value with changes in fair value recognized as either a gain or loss in earnings.

 

The result of this accounting treatment is that the fair value of the derivative instrument is marked-to-market each balance sheet date and with the change in fair value recognized in the statement of operations as other income or expense.

 

Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation and then that the related fair value is removed from the books. Gains or losses on debt extinguishment are recognized in the statement of operations upon conversion, exercise or cancellation of a derivative instrument after any shares issued in such a transaction are recorded at market value. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Instruments that become a derivative after inception are recognized as a derivative on the date they become a derivative with the offsetting entry recorded in earnings.

 

The Company determines the fair value of derivative instruments and hybrid instruments, considering all of the rights and obligations of each instrument, based on available market data using the Black-Scholes model, adjusted for the effect of dilution, because it embodies all of the requisite assumptions (including trading volatility, estimated terms, dilution and risk-free rates) necessary to fair value these instruments. For instruments in default with no remaining time to maturity the Company uses a one-year term for their years to maturity estimate unless a sooner conversion date can be estimated or is known. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques (such as Black-Scholes model) are highly volatile and sensitive to changes in the trading market price of our common stock.

 

Reclassifications

 

Certain account balances from prior periods have been reclassified in the current period financial statements so as to conform to current period classifications.

 

Recent Accounting Pronouncements

 

There are no recently issued accounting pronouncements that the Company has not yet adopted that they believe are applicable or would have a material impact on the financial statements of the Company.

 

NOTE 2: GOING CONCERN

 

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has suffered recurring losses and used significant cash in support of its operating activities and the Company’s cash position is not sufficient to support the Company’s operations. Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities as well as a series of grants. The Company requires funding of approximately $1.5 million annually to maintain current operating activities. Over the next 12 to 24 months, the Company believes it will cost approximately $5.0 million to $10.0 million to fund: (1) the FDA approval process and initial deployment of the brachytherapy products, and (2) initiate regulatory approval processes outside of the United States. The continued deployment of the brachytherapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or additional capital raises.

 

Following receipt of required regulatory approvals and financing, in the U.S., the Company intends to outsource material aspects of manufacturing, distribution, sales and marketing. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy.

 

In the longer-term, subject to the Company receiving adequate funding, regulatory approval for RadioGel™ and other brachytherapy products, and thereafter being able to successfully commercialize its brachytherapy products, the Company intends to consider resuming research efforts with respect to other products and technologies intended to help improve the diagnosis and treatment of cancer and other illnesses

 

Based on the Company’s financial history since inception, its auditor has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations.

 

As of June 30, 2018, the Company has no cash. There are currently commitments to vendors for products and services purchased, plus, the employment agreements of the CEO and CFO of the Company that will necessitate liquidation of the Company if it is unable to raise additional capital. The current level of cash is not enough to cover the fixed and variable obligations of the Company.

 

Assuming the Company is successful in the Company’s sales/development effort, it believes that it will be able to raise additional funds through strategic agreements or the sale of the Company’s stock to either current or new stockholders. There is no guarantee that the Company will be able to raise additional funds or to do so at an advantageous price.

 

The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financing and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There is no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

 -5- 

 

NOTE 3: FIXED ASSETS

 

Fixed assets consist of the following at June 30, 2018 and December 31, 2017:

 

   June 30,
2018		   December 31,
2017		 
Production equipment  $15,182   $15,182 
Less accumulated depreciation   (15,182)   (15,182)
   $-   $- 

 

Depreciation expense for the above fixed assets for the three months ended June 30, 2018 and 2017, respectively, was $0 and $733 and for the six months ended June 30, 2018 and 2017, respectively, was $0 and $1,473.

 

NOTE 4: RELATED PARTY TRANSACTIONS

 

Related Party Convertible Notes Payable

 

In March 2017, the Company combined Outstanding Notes owed to a director and major stockholder, along with $51,576 of accrued interest payable, into one promissory note (the “Related Party Note”). The Related Party Note accrues interest at a rate of 10% and was due and payable on December 31, 2017. The note holder agreed to an extension of the due date until May 9, 2018. As of June 30, 2018 and December 31, 2017 the balance of the Related Party Note was $383,771 and $383,771, respectively, and the accrued interest payable on the Related Party Note was $48,261 and $29,230, respectively.

 

Related Party Payables

 

The Company periodically receives advances for operating funds from related parties or has related parties make payments on the Company’s behalf. As a result of these activities the Company had related party payables of $82,572 and $57,297 as of June 30, 2018 and December 31, 2017, respectively.

 

Preferred Shares Issued to Officers

 

During 2017, the Company issued 100,000 shares of its Series A Preferred to its CEO, in exchange for $32,308 of accrued payroll, $67,692 of accounts payable, and wages valued at $199,690.

 

During 2017, the Company issued 83,279 shares of its Series A Preferred to its CFO, in exchange for $83,280 of accrued payroll and wages valued at $166,299.

 

Rent Expenses

 

The Company was renting office space from a significant shareholder and director of the Company on a month-to-month basis with a monthly payment of $1,500. This rental agreement was terminated as of April 1, 2017.

 

Rental expense was $0 and $4,500 for each of the three months ended June 30, 2018 and 2017 and is recorded in general and administrative expense.

 

 -6- 

 

NOTE 5: CONVERTIBLE NOTES PAYABLE

 

As of June 30, 2018 and December 31, 2017 the Company had the following convertible notes outstanding:

 

    June 30, 2018     December 31, 2017  
   

Principal

(net)

     Accrued Interest    

Principal

(net)

     Accrued Interest  
July and August 2012 $1,060,000 Notes convertible into common stock at $4.60 per share, 12% interest, due December 2013 and January 2014   $ 45,000     $ 31,888     $ 45,000       29,218  
May through October 2015 $605,000 Notes convertible into preferred stock at $1 per share, 8-10% interest, due September 30, 2015     -       17,341       -       17,341  
October through December 2015 $613,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016, net of debt discount of $0 and $0, respectively     -       5,953       -       5,953  
January through March 2016 $345,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016     -       696       -       696  
May 2017 $2,332,305 Notes convertible into common stock after April 15, 2018 at a 45% discount to lowest trade price for previous 30 days ($0.0017 at June 30, 2018), 7.5% interest, due May 2018 therefore in default as of June 30, 2018, net of debt discounts of $0 and $544,845, respectively     2,332,305       200,087       1,833,310       178,304  
May 2017 $530,539 Notes convertible into common stock after April 15, 2018 at a 45% discount to lowest trade price for previous 30 days ($0.0017 at June 30, 2018), 7.5% interest, due May 2018, net of debt discounts of $0 and $147,335, respectively     530,539       58,890       500,703       52,831  
May 2017 $76,379 Notes convertible after April 15, 2018 into common stock at a 45% discount to lowest trade price for previous 30 days ($0.0017 at June 30, 2018), 7.5% interest, due May 2018 therefore in default as of June 30, 2018, net of debt discounts of $0 and $25,085, respectively     76,379       16,724       85,227       15,773  
November 2017 $166,666 Note convertible at maturity at a 50% discount to lowest trade price for previous 25 days ($0.0015 at June 30, 2018), with a one-time interest charge of 10%, due April 15, 2018 therefore in default as of June 30, 2018, net of debt discounts of $0 and $74,662, respectively     166,666       96,667       92,004       16,667  
                                 
Penalties on notes in default     7,918       -       7,028       -  
Total Convertible Notes Payable, Net   $ 3,158,807     $ 428,246     $ 2,563,272     $ 316,784  

 

NOTE 6: DERIVATIVE LIABILITY

 

During the six months ended June 30, 2018 the Company had certain convertible notes become convertible on a set date at variable conversion rates. Upon becoming convertible the Company bifurcated the embedded conversion feature and recorded a derivative liability at fair value with the offsetting entry recorded in the statement of operations. The activity in the derivative liability account during the six months ended June 30, 2018 is summarized as follows:

 

Derivative Liability at December 31, 2017  $- 
Derivative Liability Recorded   4,636,517 
Elimination of Liability on Conversion   (271,851)
Change in Fair Value   867,608 
Derivative Liability at June 30, 2018  $5,232,274 

 

The Company uses the Black-Scholes pricing model to estimate fair value for those instruments convertible into common stock at inception, at conversion date, and at each reporting date.  During the six months ended June 30, 2018 the Company used the following assumptions in their Black-Scholes model:

 

Risk-free interest rate   1.62% - 2.35%
Expected life in years   0.12 - 1.10 
Dividend yield   0%
Expected volatility   174.46% - 221.03%

 

NOTE 7: COMMON STOCK OPTIONS AND WARRANTS

 

Common Stock Options

 

The Company recognizes in the financial statements compensation related to all stock-based awards, including stock options and warrants, based on their estimated grant-date fair value. The Company has estimated expected forfeitures and is recognizing compensation expense only for those awards expected to vest. All compensation is recognized by the time the award vests.

 

 -7- 

 

The following schedule summarizes the changes in the Company’s stock options:

 

           Weighted       Weighted 
   Options Outstanding   Average       Average 
   Number   Exercise   Remaining   Aggregate   Exercise 
   Of   Price   Contractual   Intrinsic   Price 
   Shares   Per Share   Life   Value   Per Share 
                     
Balance at December 31, 2017   1,222,500   $0.50-15     2.91 years    $-   $1.08 
                          
Options granted   -   $-    -        $- 
Options exercised   -   $-    -        $- 
Options expired   -   $-    -               $- 
                          
Balance at June 30, 2018   1,222,500   $0.50-15     2.42 years    $-   $1.08 
                          
Exercisable at June 30, 2018   1,222,500   $0.50-15     2.42 years    $-   $1.08 

 

During the three and six months ended June 31, 2018 the Company recognized $21,645 and $45,400 worth of stock based compensation related to the vesting of its stock options.

 

Common Stock Warrants

 

The following schedule summarizes the changes in the Company’s stock warrants:

 

       Weighted       Weighted 
   Warrants Outstanding   Average       Average 
   Number   Exercise   Remaining   Aggregate   Exercise 
   Of   Price   Contractual   Intrinsic   Price 
   Shares   Per Share   Life   Value   Per Share 
                     
Balance at December 31, 2017   304,200   $0.40-10     1.19 years    $-   $2.63 
                          
Warrants granted   -   $-    -        $  
Warrants exercised   -   $-    -        $   
Warrants expired/cancelled   400   $-    -        $6.00 
                                     
Balance at June 30, 2018   303,800   $0.40-10     0.70 years    $-   $2.63 
                          
Exercisable at June 30, 2018   303,800   $0.40-10     0.70 years    $-   $2.63 

 

 -8- 

 

Restricted Stock Units

 

The following schedule summarizes the changes in the Company’s restricted stock units:

 

       Weighted 
   Number   Average 
   Of   Grant Date 
   Shares   Fair Value 
         
Balance at December 31, 2017   5,740,000   $0.07 
           
RSU’s granted   -   $- 
RSU’s vested   (1,240,000)  $- 
RSU’s forfeited   -   $- 
           
Balance at June 30, 2018   4,500,000   $0.07 

 

During the three and the six months ended June 30, 2018 the Company recognized $32,801 and $84,895 worth of expense related to the vesting of its RSU’s. As of June 30, 2018, the Company had $269,534 worth of expense yet to be recognized for RSU’s not yet vested.

 

NOTE 8: STOCKHOLDERS’ EQUITY

 

Common Stock

 

During the six months ending June 30, 2018 the Company issued 41,146,060 shares of its common stock valued at $376,181 for conversion of convertible debt, 10,000 shares of its common stock valued at $449 for services, 9,666,670 shares of its common stock valued at $3,972,942 for conversions of 966,667 shares of Series A Preferred, and 1,240,000 shares of its common stock valued at $1,240 in the form of Restricted Stock Units.

 

 -9- 

 

NOTE 9: SUPPLEMENTAL CASH FLOW INFORMATION

 

During the six months ending June 30, 2018 the Company had the following non-cash investing and financing activities:

 

  ● Exchanged $32,279 of accounts payable for a one year, 18% Promissory note.
     
  ● Issued 9,666,670 shares of common stock in exchange for 966,667 shares of Series A Preferred decreasing preferred stock by $3,972,942, increasing common stock by $9,667, and increasing paid in capital by $3,963,275.
     
  ● Increased common stock and decreased paid in capital by $1,240 due to the vesting of restricted stock units.
     
  ● Issued 41,146,060 shares of common stock in exchange for convertible note principal of $197,283 and accrued interest of $3,439, reducing the derivative liability by $271,851.

 

NOTE 10: COMMITMENTS AND CONTINGENCIES

 

The Company is continuing work on many avenues to find the money needed to fund operations and provide sufficient funds needed to bring its product to market.  The Company entered into an agreement in May 2018 to find accredited investors for funding the Company under which it will pay a 5% finders fee of the gross proceeds for any financing made available to the Company plus common stock shares equal to 5% of the aggregate proceeds divided by the price per share of common stock issued in connection with the financing.

 

NOTE 11: SUBSEQUENT EVENTS

 

  ● In July and August 2018, the Company received $13,645 as a loan from a Director.
     
    In July 2018, the Company issued a six month, 8%, convertible promissory note for $50,000.
     
  ●

In July and August 2018, the Company issued 255,759,303 shares of common stock in exchange for $418,168 of convertible debt and $17,745 of accrued interest.

     
  ● In July 2018, the Company issued 410,160 shares of common stock for 41,016 shares of Series A Preferred.

 

The Company has evaluated subsequent events through the date of this filing pursuant to ASC Topic 855 and has determined that, except as disclosed herein, there are no additional subsequent events to disclose.

 

 -10- 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Except for statements of historical fact, certain information described in this Form 10-K report contains “forward-looking statements” that involve substantial risks and uncertainties. You can identify these statements by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will,” “would” or similar words. The statements that contain these or similar words should be read carefully because these statements discuss the Company’s future expectations, including its expectations of its future results of operations or financial position, or state other “forward-looking” information. Vivos Inc. believes that it is important to communicate its future expectations to its investors. However, there may be events in the future that the Company is not able to accurately predict or to control. Further, the Company urges you to be cautious of the forward-looking statements which are contained in this Form 10-Q report because they involve risks, uncertainties and other factors affecting its operations, market growth, service, products and licenses. The risk factors in the section captioned “Risk Factors” in Item 1A of the Company’s previously filed Form 10-K, as well as other cautionary language in this Form 10-Q report, describe such risks, uncertainties and events that may cause the Company’s actual results and achievements, whether expressed or implied, to differ materially from the expectations the Company describes in its forward-looking statements. The occurrence of any of the events described as risk factors could have a material adverse effect on the Company’s business, results of operations and financial position.

 

General Statement of Business

 

Vivos Inc. (the “Company” or “we”) was incorporated under the laws of Delaware on December 23, 1994 as Savage Mountain Sports Corporation (“SMSC”). On December 28, 2017, the Company changed its name from Advanced Medical Isotope Corp. to Vivos Inc. The Company has authorized capital of 2,000,000,000 shares of common stock, $0.001 par value per share, and 20,000,000 shares of preferred stock, $0.001 par value per share.

 

Our principal place of business is 719 Jadwin Avenue, Richland, Washington 99352. Our telephone number is (509) 736-4000. Our corporate website address is http://www.radiogel.com. Our common stock is currently listed for quotation on the OTC Pink Marketplace under the symbol “RDGL.”

 

Overview

 

The Company is a radiation oncology medical device company engaged in the development of its yttrium-90 based brachytherapy device, RadioGel™, for the treatment of non-resectable tumors. A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead the Company’s development efforts. The Company’s overall vision is to globally empower physicians, medical researchers and patients by providing them with new isotope technologies that offer safe and effective treatments for cancer.

 

The Company’s current focus is on the development of our RadioGel™ device candidate, including obtaining approval from the Food and Drug Administration (“FDA”) to market and sell RadioGel™ as a Class II medical device. RadioGel™ is an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals. RadioGel™ is comprised of a hydrogel, or a substance that is liquid at room temperature and then gels when reaching body temperature after injection into a tumor. In the gel are small, one micron, yttrium-90 phosphate particles (“Y-90”). Once injected, these inert particles are locked in place inside the tumor by the gel, delivering a very high local radiation dose. The radiation is beta, consisting of high-speed electrons. These electrons only travel a short distance so the device can deliver high radiation to the tumor with minimal dose to the surrounding tissue. Optimally, patients can go home immediately following treatment without the risk of radiation exposure to family members. Since Y-90 has a half-life of 2.7 days, the radioactivity drops to 5% of its original value after ten days.

 

 -11- 

 

The Company’s lead brachytherapy products, including RadioGel™, incorporate patented technology developed for Battelle Memorial Institute (“Battelle”) at Pacific Northwest National Laboratory, a leading research institute for government and commercial customers. Battelle has granted the Company an exclusive license to patents covering the manufacturing, processing and applications of RadioGel™ (the “Battelle License”). This exclusive license is to terminate upon the expiration of the last patent included in this agreement. Other intellectual property protection includes proprietary production processes and trademark protection in 17 countries. The Company plans to continue efforts to develop new refinements on the production process, and the product and application hardware, as a basis for future patents.

 

Regulatory History

 

Human Therapy

 

RadioGel™ has a long regulatory history with the Food and Drug Administration (“FDA”). Initially, the Company submitted a presubmission (Q130140) to obtain FDA feedback about the proposed product. The FDA requested that the Company file a request for designation with the Office of Combination Products (RFD130051), which led to the determination that RadioGel™ is a device for human therapy for non-resectable cancers, which must be reviewed and ultimately regulated by the Center for Devices and Radiological Health (“CDRH”). The Company then submitted a 510(k) notice for RadioGel™ (K133368), which was found Not Substantially Equivalent due to the lack of a suitable predicate, and RadioGel™ was assigned to the Class III product code NAW (microspheres). Class III products or devices are generally the highest risk devices and are therefore subject to the highest level of regulatory review, control and oversight. Class III products or devices must typically be approved by FDA before they are marketed. Class II devices represent lower risk products or devices than Class III and require fewer regulatory controls to provide reasonable assurance of the product’s or device’s safety and effectiveness. In contrast, Class I products and devices are deemed to be lower risk than Class II of III, and are therefore subject to the least regulatory controls.

 

A pre-submission meeting (Q140496) was held with the FDA on June 17, 2014, during which the FDA maintained that RadioGel™ should be considered a Class III device and therefore subject to pre-market approval. On December 29, 2014, the Company submitted a de novo petition for RadioGel™ (DEN140043). The de novo petition was denied by the FDA on June 1, 2015, with the FDA providing numerous comments and questions. On September 29, 2015, the Company submitted a follow-up pre-submission informational meeting request with the FDA (Q151569). This meeting took place on November 9, 2015, at which the FDA indicated acceptance of the Company’s applied dosimetry methods and clarified the FDA’s outstanding questions regarding RadioGel™. Following the November 2015 pre-submission meeting, the Company prepared a new pre-submission package to obtain FDA feedback on the proposed testing methods, intended to address the concerns raised by the FDA staff and to address the suitability of RadioGel™ for de novo reclassification. This pre-submission package was presented to the FDA in a meeting on August 29, 2017. During the August 2017 meeting, the FDA clarified their position on the remaining pre-clinical testing needed for RadioGel™. Specifically, the FDA addressed proposed dosimetry calculating techniques, dosimetry distribution between injections, hydrogel viscoelastic properties, and the details of the Company’s proposed animal testing.

 

The Company believes that its submissions to the FDA to date have taken into account all the FDA staff’s feedback over the past three years. Of particular importance, the Company has provided corresponding supporting data for proposed future testing of RadioGel™ to address any remaining questions raised by the FDA. We believe, although no assurances can be given, that the clinical testing modifications presented to the FDA in August 2017 will result in a de novo reclassification for RadioGel™ by the FDA. In addition, in previous FDA submittals, the Company proposed applying RadioGel™ for a very broad range of cancer therapies, referred to as Indication for Use. The FDA requested that the Company reduce its Indications for Use. To comply with that request, the Company expanded its Medical Advisory Board (“MAB”) and engaged doctors from respected hospitals who have evaluated the candidate cancer therapies based on three criteria: (1) potential for FDA approval and successful therapy. (2) notable advantage over current therapies. and (3) probability of wide spread acceptance by the medical community.

 

 -12- 

 

The MAB selected eighteen applications for RadioGel™, each of which meet the criteria described above. This large number confirms the wide applicability of the device and defines the path for future business growth. The Company’s application establishes a single Indication for Use - treatment of basal cell and squamous cell skin cancers. We anticipate that this initial application will facilitate each subsequent application for additional Indications for Use, and the testing for many of the subsequent applications could be conducted in parallel, depending on available resources.

 

In the event the FDA denies the Company’s application for de novo review, and therefore determines that RadioGel™ cannot be classified as a Class I or Class I1 device, the Company will then need to submit a pre-market approval application to obtain the necessary regulatory approval as a Class III device.

 

Animal Therapy

 

As noted above, the Office of Combination Products previously classified RadioGel™ as a device for human therapy for non-sectable cancers. In January 2018, the Center for Veterinary Medicine Product Classification Group ruled that RadioGel™ should be classified as a device for animal therapy of feline sarcomas and canine soft tissue sarcomas. In addition, the FDA also reviewed and approved our label, which is a requirement for any device used in animals. We expect the result of such classification and label approval is that no additional regulatory approvals are necessary for the use of RadioGel™ for the treatment of skin cancer in animals.

 

Based on the FDA’s recommendation, RadioGel™ will be marketed as “IsoPet® for use by veterinarians to avoid any confusion between animal and human therapy. The Company already has trademark protection for the “IsoPet®” name. IsoPet® and RadioGel™ are used synonymously throughout this document. As we stated the only distinction between the two is the FDA’s recommendation we use IsoPet® for all veterinarian usage and reserve RadioGel™ for human therapy.

 

IsoPet® Solutions

 

The Company’s IsoPet® Solutions division was established in May 2016 to focus on the veterinary oncology market, namely engagement of university veterinarian hospital to develop the detailed therapy procedures to treat animal tumors and ultimately use of the technology in private clinics. The Company has worked with four different university veterinarian hospitals on RadioGel™ testing and therapy. Colorado State University demonstrated the procedures and the CT and PET-CT imaging of RadioGel™. Washington State University treated five cats for feline sarcoma. They concluded that the product was safe and effective in killing cancer cells. A contract was signed with University of Missouri to treat canine sarcomas and equine sarcoids starting early in 2019. The safety review at UC Davis is almost completed. They will be treating prostate and liver cancer in canines in 2019.

 

These animal therapies will generate the additional data required by the private veterinary clinics to assure them of the safety and efficacy of IsoPet® to complement the previous work at Washington State University.

 

The Company anticipates that future profit will be derived from direct sales of RadioGel™ (under the name IsoPet®) and related services, and from licensing to private medical and veterinary clinics in the U.S. and internationally.

 

Based on the Company’s financial history since inception, its auditor has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and not be able to continue operations.

 

 -13- 

 

Results of Operations

 

Comparison of the Three Months Ended June 30, 2018 and 2017

 

The following table sets forth information from our statements of operations for the three months ended June 30, 2018 and 2017.

 

   Three Months Ended
June 30, 2018		   Three Months Ended
June 30, 2017		 
Revenues  $-   $- 
Operating expenses   (341,900)   (619,171)
Operating loss   (341,900)   (619,171)
Non-operating income (expense):          
Gain (loss) on debt extinguishment   131,604    (201,574)
Gain (loss) on derivative liability   (867,608)   83,089 
Interest expense   (4,934,066)   (781,139)
Net income (loss)  $(6,011,970)  $(1,518,795)

 

Revenue

 

Revenue was $0 for the three months ended June 30, 2018 and June 30, 2017.

 

Operating Expenses

 

Operating expenses for the three months ended June 30, 2018 and 2017 consists of the following:

 

   Three months ended
June 30, 2018		   Three months ended
June 30, 2017		 
Depreciation and amortization expense  $-   $733 
Professional fees   145,220    295,544 
Reserved stock units granted   32,801    - 
Stock options granted   21,645    27,059 
Payroll expenses   82,200    181,494 
Research and development   41,766    80,523 
General and administrative expenses   15,318    18,567 
Sales and marketing expense   2,950    15,251 
Total operating expenses  $341,900   $619,171 

 

Operating expenses for the three months ended June 30, 2018 and 2017 was $341,900 and $619,171, respectively. The decrease in operating expenses from 2017 to 2018 can be attributed to the decrease in payroll expense ($181,494 for the three months ended June 30, 2017 versus $82,200 for the three months ended June 30, 2018); decrease in professional fees expenses ($295,544 for the three months ended June 30, 2017 versus $145,220 for the three months ended June 30, 2018; decrease in sales and marketing expense ($15,251 for the three months ended June 30, 2017 versus $2,950 for the three months ended June 30, 2018; decrease in research and development ($80,523 for the three months ended June 30, 2017 versus $41,766 for the three months ended June 30, 2018; and the decrease in general and administrative expense ($18,567 for the three months ended June 30, 2017 versus $15,318 for the three months ended June 30, 2018). These decreases in operating expenses were partially offset by an increase in reserved stock units granted ($32,801 for the three months ended June 30, 2018 versus $0 for the three months ended June 30, 2017).

 

 -14- 

 

Non-Operating Income (Expense)

 

Non-operating income (expense) for the three months ended June 30, 2018 and 2017 consists of the following:

 

    Three months ended
June 30, 2018		     Three months ended
June 30, 2017		  
Interest expense   $ (4,934,066 )   $ (781,139 )
Net (gain) loss on debt extinguishment     131,604       (201,574 )
(Gain) loss on derivative liability     (867,608 )     83,089  
Non-operating income (expense)   $ (5,670,070 )   $ (899,624 )

 

Non-operating income (expense) for the three months ended June 30, 2018 varied from the three months ended June 30, 2017 primarily due to a loss on debt extinguishment of $201,574 for the three months ended June 30, 2017 versus a gain of $131,604 for the three months ended June 30, 2018; a gain on derivative liability for the three months ended June 30, 2017 of $83,089 versus a loss of $867,608 for the three months ended June 30, 2018; and an increase in interest expense from $781,139 for the three months ended June 30, 2017 to $4,934,066 for the three months ended June 30, 2018. The majority of the interest recorded by the Company consists of amortization of debt discount and derivative liabilities.

 

Net Loss

 

Our net income (loss) for the three months ended June 30, 2018 and 2017 was $(6,011,970) and $(1,518,795), respectively.

 

Comparison of the Six Months Ended June 30, 2018 and 2017

 

The following table sets forth information from our statements of operations for the six months ended June 30, 2018 and 2017.

 

  

Six Months

Ended

June 30, 2018

  

Six Months

Ended

June 30, 2017

 
Revenues  $-   $4,054 
           
Operating expenses   628,594    987,940 
           
Operating loss   (628,594)   (983,886)
Non-operating income (expense)          
Interest expense   (5,566,140)   (1,309,090)
Net gain on sale of assets   -    2,800 
Grants received   17,583    - 
Net gain (loss) on debt extinguishment   131,604    (53,863)
Gain (loss) on derivative liability   (867.608)   408,479)
Net Income (Loss)  $(6,913,155)  $(1,935,560)

 

 -15- 

 

Revenue

 

Revenue was $4,054 for the six months ended June 30, 2017, compared to $0 for the six months ended June 30, 2018, a period over period decrease of $4,054. The decrease was a result of a loss of consulting revenue, currently our only source of revenue, during the first half of the fiscal year. Consulting revenue consists of providing clients with assistance in strategic targetry services, and research into production of radiopharmaceuticals and the operations of radioisotope production facilities. No proprietary information belonging to our Company is shared during the process of this consulting. Consulting services had been our only source of revenue. The Company does not have any current contracts or arrangements for consulting services, and, until such time as the Company secures contracts or arrangements to provide consulting services, the Company does not expect to generate any additional revenue during the third or fourth quarter of 2018 and beyond.

 

Management does not anticipate that the Company will generate revenue sufficient to sustain operations until such time as the Company secures revenue-generating arrangements with respect to RadioGel™ and/or any of our other brachytherapy technologies.

 

Operating Expense

 

Operating expenses for the six months ended June 30, 2018 and 2017 consists of the following:

 

  

Six months

ended

June 30, 2018

  

Six months

ended

June 30, 2017

 
Depreciation and amortization expense  $-   $1,473 
Professional fees   215,278    430,148 
Reserved stock units granted   84,895    - 
Stock options granted   45,400    55,299 
Payroll expenses   161,070    286,275 
Research and development   74,580    113,409 
General and administrative expenses   34,421    60,087 
Sales and marketing expense   12,950    41,249 
Total operating expenses  $628,594   $987,940 

 

Operating expenses for the six months ended June 30, 2018 and 2017 was $628,594 and $987,940, respectively. The decrease in operating expenses from 2017 to 2018 can be attributed to the decrease in professional fees expense from 2017 to 2018 ($430,148 for the six months ended June 30, 2017 versus $215,278 for the six months ended June 30, 2018); a decrease in sales and marketing expense from 2017 to 2018 ($41,249 for the six months ended June 30, 2017 versus $12,950 for the six months ended June 30, 2018); a decrease in stock options granted from 2017 to 2018 ($55,299 for the six months ended June 30, 2017 versus $45,400 for the six months ended June 30, 2018); a decrease in payroll expenses from 2017 to 2018 ($286,275 for the six months ended June 30, 2017 versus $161,070 for the six months ended June 30, 2018); a decrease in research and development from 2017 to 2018 ($113,409 for the six months ended June 30, 2017 versus $74,580 for the six months ended June 30, 2018; and the decrease in general and administrative expense ($60,087 for the six months ended June 30, 2017 versus $34,421 for the six months ended June 30, 2018). The decrease in operating expenses was partially offset by an increase in reserved stock units granted from 2017 to 2018 ($84,895 for the six months ended June 30, 2018 versus $0 for the six months ended June 30, 2017).

 

Non-Operating Income (Expense)

 

Non-Operating income (expense) for the six months ended June 30, 2018 and 2017 consists of the following:

 

  

Six months

ended

June 30, 2018

  

Six months

ended

June 30, 2017

 
Interest expense  $(5,566,140)  $(1,309,090)
Net gain on sale of assets   -    2,800 
Grants received   17,583    - 
Net gain (loss) on debt extinguishment   131,604    (53,863)
Gain (loss) on derivative liability   (867,608)   408,479 
Non-operating income (expense)  $(6,284,561)  $(951,674)

 

 -16- 

 

The Company had non-operating expense of $951,674 during the six months ended June 30, 2017, as compared to non-operating expense of $6,284,561 during the six months ended June 30, 2018. As shown above, this increase in non-operating expense is primarily due to a gain on debt extinguishment of $131,604 for the six months ended June 30, 2018, as compared to a loss of $53,863 during the same period in 2017. The Company’s gain on derivative liability decreased from $408,479 during the six months ended June 30, 2017, as compared to a loss of $867,608 for the six months ended June 30, 2018. Additionally, the Company experienced a increase in interest expense from $1,309,090 for the six months ended June 30, 2017, as compared to $5,566,140 for the six months ended June 30, 2018.

 

Net Gain (Loss)

 

Our net income (loss) for the six months ended June 30, 2018 and 2017 was $(6,913,155) and $(1,935,560) respectively.

 

Liquidity and Capital Resources

 

At June 30, 2018, the Company had negative working capital of $5,444,985, as compared to $4,262,470 at December 31, 2017. During the six months ended June 30, 2018 the Company experienced negative cash flow from operations of $96,876 and it received $0 for investing activities while adding $88,559 of cash flows from financing activities. As of June 30, 2018, the Company had no commitments for capital expenditures.

 

Cash used in operating activities decreased from $776,944 for the six month period ending June 30, 2017 to $96,876 for the six month period ending June 30, 2018. Cash used in operating activities was primarily a result of the Company’s net loss, partially offset by non-cash items, such as loss on derivative liability and amortization and depreciation, included in that net loss and preferred and common stock issued for services and other expenses. The Company received $0 and $2,800 in cash from investing activities for the six month periods ended June 30, 2018 and 2017, respectively. Cash provided from financing activities decreased from $1,115,703 for the six month period ending June 30, 2017 to $88,559 for the six month period ending June 30, 2018. The decrease in cash provided from financing activities was primarily a result of decrease in proceeds from convertible debt, as well as a decrease in shareholder advances.

 

The Company has generated material operating losses since inception. The Company had a net loss of $6,913,155 for the six months ended June 30, 2018, and a net loss of $1,935,560 for the six months ended June 30, 2017. The Company expects to continue to experience net operating losses. Historically, the Company has relied upon investor funds to maintain its operations and develop the Company’s business. The Company anticipates raising additional capital within the next twelve months from investors for working capital as well as business expansion, although the Company can provide no assurance that additional investor funds will be available on terms acceptable to the Company. If the Company is unable to obtain additional financing to meet its working capital requirements, it may have to curtail its business.

 

 -17- 

 

The Company anticipates raising additional capital within the next twelve months from investors for working capital as well as business expansion, although the Company can provide no assurance that additional investor funds will be available on terms acceptable to the Company. If the Company is unable to obtain additional financing to meet its working capital requirements, it may have to cease operations.

 

The Company requires funding of at least $1.5 million per year to maintain current operating activities. Over the next 12 to 24 months, the Company believes it will cost approximately $11.0 million to fund: (1) the FDA approval process and initial deployment of RadioGel™ and other brachytherapy products. The continued deployment of the Company’s brachytherapy products, including RadioGel™, and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies, which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or additional capital raises.

 

Although the Company is seeking to raise additional capital and has engaged in numerous discussions with investment bankers and investors, the Company has not received firm commitments for the required funding. Based upon its discussions, the Company anticipates that if the Company is able to obtain the funding required to retire outstanding debt, pay past due payables and maintain its current operating activities, that the terms thereof will be materially dilutive to existing shareholders.

 

Recent geopolitical events, including the inherent instability and volatility in global capital markets, as well as the lack of liquidity in the capital markets, could impact the Company’s ability to obtain financing and its ability to execute its business plan.

 

Accounting Policies and Estimates

 

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ from these estimates under different assumptions or conditions. During the period ended June 30, 2018, we believe there have been no significant changes to the items disclosed as significant accounting policies in management’s notes to the consolidated financial statements in our annual report on Form 10-K for the year ended December 31, 2017, filed on April 2, 2018.

 

 -18- 

 

Off-Balance Sheet Arrangements

 

The Company does not have any off balance sheet arrangements that are reasonably likely to have a current or future effect on the Company’s financial condition, revenues, results of operations, liquidity or capital expenditures.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

This item is not applicable to us because we are a smaller reporting company as defined by Rule 12b-2 under the Securities Exchange Act of 1934.

 

Item 4. Controls and Procedures.

 

Disclosure Controls and Procedures

 

Based on an evaluation as of the date of the end of the period covered by this report, the Company’s Chief Executive Officer and Chief Financial Officer conducted an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures, as required by Exchange Act Rule 13a-15. Based on that evaluation, the Company’s Chief Executive Officer and Chief Financial Officer concluded that, because of the disclosed material weaknesses in the Company’s internal control over financial reporting, the Company’s disclosure controls and procedures were ineffective as of the end of the period covered by this report to ensure that information required to be disclosed by the Company in the reports that the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms.

 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in the Company’s reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the Company’s reports filed under the Exchange Act is accumulated and communicated to management, including the Company’s Chief Executive Officer and the Company’s Chief Financial Officer, to allow timely decisions regarding required disclosure.

 

Changes in Internal Control Over Financial Reporting

 

There have been no changes in the Company’s internal control over financial reporting that occurred during the period ended June 30, 2018 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

The term “internal control over financial reporting” is defined as a process designed by, or under the supervision of, the registrant’s principal executive and principal financial officers, or persons performing similar functions, and effected by the registrant’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

 

(a) Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the registrant;
   
(b) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the registrant are being made only in accordance with authorizations of management and directors of the registrant; and
   
(c) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the registrant’s assets that could have a material effect on the financial statements.

 

 -19- 

 

PART II

 

Item 1. Legal Proceedings

 

In 2016, the Company was awarded in the Superior Court of the State of Washington a total sum of $527,876 against BancLeasing. The Company is pursuing its options for collection of the awarded amount, however there can be no assurance as to any eventual collection.

 

Item 2. Unregistered Sales of Equity Securities

 

During the six months ending June 30, 2018 the Company issued 10,000 common shares for services.

 

During the six months ending June 30, 2018 the Company issued 9,666,670 common shares in exchange for 966,667 shares Series A Preferred.

 

In connection with the above stock sales, we did not pay any underwriting discounts or commissions. None of the sales of securities described or referred to above was registered under the Securities Act of 1933, as amended (the “Securities Act”). We had or one of our affiliates had a prior business relationship with each of the purchasers, and no general solicitation was used in connection with the sales. In making the sales without registration under the Securities Act, we relied upon the exemption from registration contained in Section 4(a)(2) of the Securities Act.

 

Item 6. Exhibits.

 

Exhibit    
Number   Description
     
31.1*   Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes – Oxley Act of 2002
     
31.2*   Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes – Oxley Act of 2002
     
32.1*   Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350
     
101.INS   XBRL Instance Document
     
101.SCH   XBRL Taxonomy Extension Schema
     
101.CAL   XBRL Taxonomy Extension Calculation Linkbase
     
101.DEF   XBRL Taxonomy Extension Definition Linkbase
     
101.LAB   XBRL Taxonomy Extension Label Linkbase
     
101.PRE   XBRL Taxonomy Extension Presentation Linkbase

 

* Filed herewith.

 

 -20- 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Vivos Inc.
     
Date: August 20, 2018 By: /s/ Michael Korenko
  Name: Michael K. Korenko
  Title: Chief Executive Officer
    (Principal Executive Officer)

 

Date: August 20, 2018 By: /s/ L. Bruce Jolliff
  Name: L. Bruce Jolliff
  Title: Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

 -21- 
   

 

 EX-31.1 2 ex31-1.htm

 

EXHIBIT 31.1

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Michael K. Korenko, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Vivos Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 20, 2018  
   
/s/ Michael K. Korenko  
Michael K. Korenko  
Chief Executive Officer  
(Principal Executive Officer)  

 

 
 

 EX-31.2 3 ex31-2.htm

 

EXHIBIT 31.2

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, L. Bruce Jolliff, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of Vivos Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as   defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report  based  on such  evaluation; and
     
  d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 20, 2018  
   
/s/ L. Bruce Jolliff  
L. Bruce Jolliff  

Chief Financial Officer

(Principal Financial Officer)

  

 

 
 

 EX-32.1 4 ex32-1.htm

 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the accompanying quarterly report of Vivos Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2018 (the “Report”), the undersigned, Michael Korenko, Chief Executive Officer of the Company, and L. Bruce Jolliff, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

  Date: August 20, 2018  
     
  /s/ Michael K. Korenko  
Name: Michael K. Korenko  
Title: Chief Executive Officer  
     
  /s/ L. Bruce Jolliff  
Name: L. Bruce Jolliff  
Title: Chief Financial Officer  

 

 
 

 EX-101.INS 5 rdgl-20180630.xml XBRL INSTANCE FILE 0001449349 2018-01-01 2018-06-30 0001449349 2017-12-31 0001449349 2018-06-30 0001449349 us-gaap:EquipmentMember 2017-12-31 0001449349 us-gaap:EquipmentMember 2018-06-30 0001449349 RDGL:ConvertibleNotesPayableOneMember 2017-12-31 0001449349 RDGL:ConvertibleNotesPayableOneMember 2018-06-30 0001449349 RDGL:ConvertibleNotesPayableOneMember 2018-01-01 2018-06-30 0001449349 RDGL:ConvertibleNotesPayableTwoMember 2017-12-31 0001449349 RDGL:ConvertibleNotesPayableTwoMember 2018-01-01 2018-06-30 0001449349 RDGL:ConvertibleNotesPayableThreeMember 2017-12-31 0001449349 RDGL:ConvertibleNotesPayableThreeMember 2018-01-01 2018-06-30 0001449349 RDGL:ConvertibleNotesPayableFourMember 2017-12-31 0001449349 RDGL:ConvertibleNotesPayableFourMember 2018-01-01 2018-06-30 0001449349 RDGL:ConvertibleNotesPayableFourMember 2018-06-30 0001449349 RDGL:ConvertibleNotesPayableFiveMember 2017-12-31 0001449349 RDGL:ConvertibleNotesPayableFiveMember 2018-01-01 2018-06-30 0001449349 RDGL:ConvertibleNotesPayableFiveMember 2018-06-30 0001449349 RDGL:ConvertibleNotesPayableSixMember 2017-12-31 0001449349 RDGL:ConvertibleNotesPayableSixMember 2018-01-01 2018-06-30 0001449349 RDGL:ConvertibleNotesPayableSevenMember 2017-12-31 0001449349 RDGL:ConvertibleNotesPayableSevenMember 2018-06-30 0001449349 RDGL:ConvertibleNotesPayableTwoMember 2018-06-30 0001449349 RDGL:ConvertibleNotesPayableThreeMember 2018-06-30 0001449349 RDGL:ConvertibleNotesPayableSixMember 2018-06-30 0001449349 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0001449349 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2018-01-01 2018-06-30 0001449349 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2018-01-01 2018-06-30 0001449349 us-gaap:WarrantMember 2018-01-01 2018-06-30 0001449349 us-gaap:WarrantMember srt:MinimumMember 2018-01-01 2018-06-30 0001449349 us-gaap:WarrantMember srt:MaximumMember 2018-01-01 2018-06-30 0001449349 us-gaap:FairValueInputsLevel1Member 2018-06-30 0001449349 us-gaap:FairValueInputsLevel2Member 2018-06-30 0001449349 us-gaap:FairValueInputsLevel3Member 2018-06-30 0001449349 RDGL:ConvertibleNotesPayableTwoMember srt:MinimumMember 2018-06-30 0001449349 RDGL:ConvertibleNotesPayableTwoMember srt:MaximumMember 2018-06-30 0001449349 us-gaap:EmployeeStockOptionMember 2017-12-31 0001449349 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2017-12-31 0001449349 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2017-12-31 0001449349 us-gaap:WarrantMember 2017-12-31 0001449349 us-gaap:WarrantMember srt:MinimumMember 2017-12-31 0001449349 us-gaap:WarrantMember srt:MaximumMember 2017-12-31 0001449349 us-gaap:SeriesAPreferredStockMember 2018-01-01 2018-06-30 0001449349 us-gaap:CommonStockMember 2018-01-01 2018-06-30 0001449349 RDGL:ConvertibleNotesPayableEightMember 2017-12-31 0001449349 RDGL:ConvertibleNotesPayableSevenMember 2018-01-01 2018-06-30 0001449349 RDGL:ConvertibleNotesPayableEightMember 2018-01-01 2018-06-30 0001449349 RDGL:RestrictedStockUnitsMember 2017-12-31 0001449349 RDGL:DirectorAndMajorStockholderMember 2017-03-31 0001449349 us-gaap:SeriesAPreferredStockMember RDGL:CFOMember 2017-01-01 2017-12-31 0001449349 RDGL:ShareholderAndDirectorMember 2018-01-01 2018-06-30 0001449349 us-gaap:SeriesAPreferredStockMember RDGL:CFOMember 2017-12-31 0001449349 us-gaap:SeriesAPreferredStockMember RDGL:CEOMember 2017-01-01 2017-12-31 0001449349 us-gaap:SeriesAPreferredStockMember RDGL:CEOMember 2017-12-31 0001449349 2017-01-01 2017-06-30 0001449349 2016-12-31 0001449349 srt:MinimumMember 2018-06-30 0001449349 srt:MaximumMember 2018-06-30 0001449349 RDGL:ConvertibleNotesPayableEightMember 2018-06-30 0001449349 RDGL:CommonStockOptionMember 2018-01-01 2018-06-30 0001449349 RDGL:RestrictedStockUnitsMember 2018-01-01 2018-06-30 0001449349 RDGL:RestrictedStockUnitsMember 2018-06-30 0001449349 us-gaap:EmployeeStockOptionMember 2018-06-30 0001449349 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2018-06-30 0001449349 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2018-06-30 0001449349 us-gaap:WarrantMember 2018-06-30 0001449349 us-gaap:WarrantMember srt:MinimumMember 2018-06-30 0001449349 us-gaap:WarrantMember srt:MaximumMember 2018-06-30 0001449349 RDGL:EmployeeMember 2018-01-01 2018-06-30 0001449349 RDGL:RelatedPartyNoteMember 2018-06-30 0001449349 RDGL:RelatedPartyNoteMember 2017-12-31 0001449349 RDGL:PromissoryNoteMember 2018-06-30 0001449349 RDGL:PromissoryNoteMember 2018-01-01 2018-06-30 0001449349 us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0001449349 2018-08-16 0001449349 2018-04-01 2018-06-30 0001449349 2017-04-01 2017-06-30 0001449349 2017-06-30 0001449349 RDGL:CommonStockOptionMember 2018-04-01 2018-06-30 0001449349 RDGL:RestrictedStockUnitsMember 2018-04-01 2018-06-30 0001449349 us-gaap:SubsequentEventMember 2018-07-01 2018-07-31 0001449349 us-gaap:SubsequentEventMember 2018-08-01 2018-08-31 0001449349 us-gaap:SubsequentEventMember 2018-07-31 0001449349 us-gaap:SubsequentEventMember 2018-08-31 0001449349 us-gaap:SubsequentEventMember us-gaap:SeriesAPreferredStockMember 2018-07-01 2018-07-31 0001449349 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2018-01-01 2018-06-30 0001449349 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2018-01-01 2018-06-30 0001449349 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2018-01-01 2018-06-30 0001449349 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2018-01-01 2018-06-30 0001449349 us-gaap:MeasurementInputExpectedDividendRateMember 2018-01-01 2018-06-30 0001449349 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2018-01-01 2018-06-30 0001449349 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2018-01-01 2018-06-30 0001449349 us-gaap:SubsequentEventMember RDGL:EightPercentageConvertiblePromissoryNoteMember 2018-07-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure RDGL:Number VIVOS INC 10-Q 2018-06-30 false --12-31 Smaller Reporting Company Q2 373927406 2563272 3158807 45000 45000 1833310 2332305 500703 85227 76379 530539 92004 166666 0.001 0.001 20000000 20000000 3778622 2811955 3778622 2811955 0.001 0.001 2000000000 2000000000 65695213 117757943 65695213 117757943 791938 957499 1080334 0001449349 RDGL 2018 347069 480436 15697 8161 -4262470 -10668689 -64288167 -71201322 46408443 50836259 65695 117758 3779 2811 4278167 10676850 4278167 10676850 85786 216436 840972 1040275 15697 8161 669 669 669 669 15028 7492 6711 7492 8317 78103383 42375108 88308304 46454069 -0.0836 -0.0457 -0.0681 -0.0327 -6913155 -1935560 -6011970 -1518795 -6913155 -1935560 -6011970 -1518795 -6284561 -951674 -5670070 -899624 2800 5566140 1309090 4934066 781139 -628594 -983886 -341900 -619171 628594 987940 341900 619171 34421 60087 15318 18567 161070 286275 82200 181494 215278 430148 145220 295544 1473 733 12950 41249 2950 15251 1473 0 733 8317 27889 369449 -8317 341560 88559 1115703 50000 137000 2800 -96876 -776944 137696 350468 130650 -60212 266795 39949 781 -5142 -13284 -4675 449 2800 13547780 9575805 84895 32801 5232274 5232274 1060000 345000 2332305 76379 605000 613000 530539 166666 15182 15182 15182 15182 316784 428246 29218 31888 17341 5953 696 696 178304 200087 52831 15773 16724 17341 5953 58890 16667 51576 96667 48261 29230 17745 17745 0.12 0.08 0.075 0.075 0.08 0.075 0.08 0.10 0.10 0.18 376181 418168 418168 1240000 7028 7918 4.60 1 0.0017 0.0017 1 1 0.0017 0.0015 December 2013 and January 2014 September 30, 2015 June 30, 2016 June 30, 2016 May 2018 May 2018 May 2018 April 15, 2018 Accounts payable for a one year 0 544845 0 147335 25085 0 0 0 74662 0 1240 10000 41146060 255759303 255759303 5740000 4500000 -1240000 0.07 0.07 74580 113409 41766 80523 38559 383771 383771 45400 21645 17583 -867608 408479 -867608 83089 131604 -53863 -45400 -55299 1500 83279 100000 1222500 1222500 1222500 P2Y10M28D P2Y5M1D P8M12D P2Y5M1D P8M12D 1.08 1.08 1.08 304200 303800 400 303800 0.40 10 0.40 10 0.40 10 2.63 2.63 9667 3972942 131604 -53863 131604 -201574 67692 32279 166299 199690 3963275 P1Y2M8D 6.00 2.63 32279 45400 55299 21645 27059 5000000 10000000 2017-04-01 9666670 50000 449 171090 0.50 15 0.50 15 0.50 15 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 1: BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying condensed financial statements of Vivos Inc. (the &#8220;<i>Company</i>&#8221;) have been prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and disclosures required by accounting principles generally accepted in the United States have been condensed or omitted pursuant to such rules and regulations. These condensed financial statements reflect all adjustments that, in the opinion of management, are necessary to present fairly the results of operations of the Company for the period presented. The results of operations for the six months ended June 30, 2018, are not necessarily indicative of the results that may be expected for any future period or the fiscal year ending December 31, 2018 and should be read in conjunction with the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on April 2, 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In April of 2017, the Company filed a Certificate of Merger with the Delaware Division of Corporations in order to merge the Company&#8217;s wholly-owned subsidiary, IsoPet Solutions Corporation, with and into the Company. The Company therefore no longer prepares Consolidated Financial Statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Use of Estimates</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Fair Value of Financial Instruments</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair Value of Financial Instruments, requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of June 30, 2018 and December 31, 2017, the balances reported for cash, prepaid expenses, accounts payable, and accrued expenses, approximate the fair value because of their short maturities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company measures certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis were calculated using the Black-Scholes pricing model and are as follows at June 30, 2018:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">June 30, 2018</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Total</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Level 1</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Level 2</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Level 3</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Liabilities:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%; padding-bottom: 1.5pt"><font style="font-size: 10pt">Derivative Liability</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">5,232,274</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">5,232,274</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total Liabilities Measured at Fair Value</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,232,274</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,232,274</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Derivative Liabilities</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates its convertible debt, options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with Accounting Standards Codification topic 815, Accounting for Derivative Instruments and Hedging Activities (&#8220;ASC 815&#8221;) as well as related interpretations of this standard and Accounting Standards Update 2017-11, which was adopted by the Company effective January 1, 2018. In accordance with this standard, derivative instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair values with gains or losses recognized in earnings. Embedded derivatives that are not clearly and closely related to the host contract are bifurcated and are recognized at fair value with changes in fair value recognized as either a gain or loss in earnings.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The result of this accounting treatment is that the fair value of the derivative instrument is marked-to-market each balance sheet date and with the change in fair value recognized in the statement of operations as other income or expense.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation and then that the related fair value is removed from the books. Gains or losses on debt extinguishment are recognized in the statement of operations upon conversion, exercise or cancellation of a derivative instrument after any shares issued in such a transaction are recorded at market value. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Instruments that become a derivative after inception are recognized as a derivative on the date they become a derivative with the offsetting entry recorded in earnings.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determines the fair value of derivative instruments and hybrid instruments, considering all of the rights and obligations of each instrument, based on available market data using the Black-Scholes model, adjusted for the effect of dilution, because it embodies all of the requisite assumptions (including trading volatility, estimated terms, dilution and risk-free rates) necessary to fair value these instruments. For instruments in default with no remaining time to maturity the Company uses a one-year term for their years to maturity estimate unless a sooner conversion date can be estimated or is known. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques (such as Black-Scholes model) are highly volatile and sensitive to changes in the trading market price of our common stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Reclassifications</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain account balances from prior periods have been reclassified in the current period financial statements so as to conform to current period classifications.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recent Accounting Pronouncements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are no recently issued accounting pronouncements that the Company has not yet adopted that they believe are applicable or would have a material impact on the financial statements of the Company.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 2: GOING CONCERN</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has suffered recurring losses and used significant cash in support of its operating activities and the Company&#8217;s cash position is not sufficient to support the Company&#8217;s operations. Research and development of the Company&#8217;s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities as well as a series of grants. The Company requires funding of approximately $1.5 million annually to maintain current operating activities. Over the next 12 to 24 months, the Company believes it will cost approximately $5.0 million to $10.0 million to fund: (1) the FDA approval process and initial deployment of the brachytherapy products, and (2) initiate regulatory approval processes outside of the United States. The continued deployment of the brachytherapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA&#8217;s classification of the Company&#8217;s brachytherapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company&#8217;s spending and its financing requirements would be the timing of any approvals and the nature of the Company&#8217;s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products&#8217; success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or additional capital raises.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following receipt of required regulatory approvals and financing, in the U.S., the Company intends to outsource material aspects of manufacturing, distribution, sales and marketing. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the longer-term, subject to the Company receiving adequate funding, regulatory approval for RadioGel&#8482; and other brachytherapy products, and thereafter being able to successfully commercialize its brachytherapy products, the Company intends to consider resuming research efforts with respect to other products and technologies intended to help improve the diagnosis and treatment of cancer and other illnesses</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on the Company&#8217;s financial history since inception, its auditor has expressed substantial doubt as to the Company&#8217;s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2018, the Company has no cash. There are currently commitments to vendors for products and services purchased, plus, the employment agreements of the CEO and CFO of the Company that will necessitate liquidation of the Company if it is unable to raise additional capital. The current level of cash is not enough to cover the fixed and variable obligations of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Assuming the Company is successful in the Company&#8217;s sales/development effort, it believes that it will be able to raise additional funds through strategic agreements or the sale of the Company&#8217;s stock to either current or new stockholders. There is no guarantee that the Company will be able to raise additional funds or to do so at an advantageous price.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company&#8217;s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financing and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There is no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3: FIXED ASSETS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fixed assets consist of the following at June 30, 2018 and December 31, 2017:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">June 30, </font><br /> <font style="font-size: 10pt">2018</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31, </font><br /> <font style="font-size: 10pt">2017</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font-size: 10pt">Production equipment</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">15,182</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">15,182</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less accumulated depreciation</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(15,182</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(15,182</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense for the above fixed assets for the three months ended June 30, 2018 and 2017, respectively, was $0 and $733 and for the six months ended June 30, 2018 and 2017, respectively, was $0 and $1,473.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 4: RELATED PARTY TRANSACTIONS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Related Party Convertible Notes Payable</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2017, the Company combined Outstanding Notes owed to a director and major stockholder, along with $51,576 of accrued interest payable, into one promissory note (the &#8220;<i>Related Party Note</i>&#8221;). The Related Party Note accrues interest at a rate of 10% and was due and payable on December 31, 2017. The note holder agreed to an extension of the due date until May 9, 2018. As of June 30, 2018 and December 31, 2017 the balance of the Related Party Note was $383,771 and $383,771, respectively, and the accrued interest payable on the Related Party Note was $48,261 and $29,230, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Related Party Payables</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company periodically receives advances for operating funds from related parties or has related parties make payments on the Company&#8217;s behalf. As a result of these activities the Company had related party payables of $82,572 and $57,297 as of June 30, 2018 and December 31, 2017, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Preferred Shares Issued to Officers</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2017, the Company issued 100,000 shares of its Series A Preferred to its CEO, in exchange for $32,308 of accrued payroll, $67,692 of accounts payable, and wages valued at $199,690.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2017, the Company issued 83,279 shares of its Series A Preferred to its CFO, in exchange for $83,280 of accrued payroll and wages valued at $166,299.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Rent Expenses</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company was renting office space from a significant shareholder and director of the Company on a month-to-month basis with a monthly payment of $1,500. This rental agreement was terminated as of April 1, 2017.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Rental expense was $0 and $4,500 for each of the three months ended June 30, 2018 and 2017 and is recorded in general and administrative expense.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 5: CONVERTIBLE NOTES PAYABLE</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2018 and December 31, 2017 the Company had the following convertible notes outstanding:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">June 30, 2018</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31, 2017</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Principal</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(net)</p></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Accrued Interest</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Principal</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(net)</p></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Accrued Interest</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%"><font style="font-size: 10pt">July and August 2012 $1,060,000 Notes convertible into common stock at $4.60 per share, 12% interest, due December 2013 and January 2014</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">45,000</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">31,888</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">45,000</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">29,218</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">May through October 2015 $605,000 Notes convertible into preferred stock at $1 per share, 8-10% interest, due September 30, 2015</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">17,341</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">17,341</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">October through December 2015 $613,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016, net of debt discount of $0 and $0, respectively</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,953</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,953</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">January through March 2016 $345,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">696</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">696</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">May 2017 $2,332,305 Notes convertible into common stock after April 15, 2018 at a 45% discount to lowest trade price for previous 30 days ($0.0017 at June 30, 2018), 7.5% interest, due May 2018 therefore in default as of June 30, 2018, net of debt discounts of $0 and $544,845, respectively</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,332,305</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">200,087</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,833,310</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">178,304</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">May 2017 $530,539 Notes convertible into common stock after April 15, 2018 at a 45% discount to lowest trade price for previous 30 days ($0.0017 at June 30, 2018), 7.5% interest, due May 2018, net of debt discounts of $0 and $147,335, respectively</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">530,539</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">58,890</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">500,703</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">52,831</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">May 2017 $76,379 Notes convertible after April 15, 2018 into common stock at a 45% discount to lowest trade price for previous 30 days ($0.0017 at June 30, 2018), 7.5% interest, due May 2018 therefore in default as of June 30, 2018, net of debt discounts of $0 and $25,085, respectively</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">76,379</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">16,724</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">85,227</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">15,773</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">November 2017 $166,666 Note convertible at maturity at a 50% discount to lowest trade price for previous 25 days ($0.0015 at June 30, 2018), with a one-time interest charge of 10%, due April 15, 2018 therefore in default as of June 30, 2018, net of debt discounts of $0 and $74,662, respectively</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">166,666</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">96,667</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">92,004</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">16,667</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Penalties on notes in default</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">7,918</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">7,028</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total Convertible Notes Payable, Net</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,158,807</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">428,246</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,563,272</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">316,784</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 7: COMMON STOCK OPTIONS AND WARRANTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common Stock Options</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes in the financial statements compensation related to all stock-based awards, including stock options and warrants, based on their estimated grant-date fair value. The Company has estimated expected forfeitures and is recognizing compensation expense only for those awards expected to vest. All compensation is recognized by the time the award vests.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following schedule summarizes the changes in the Company&#8217;s stock options:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Weighted</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Weighted</font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Options Outstanding</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><font style="font-size: 10pt">Average</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><font style="font-size: 10pt">Average</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Number</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Exercise</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Remaining</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Aggregate</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Exercise</font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Of</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Price</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Contractual</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Intrinsic</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Price</font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Shares</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Per Share</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Life</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Value</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Per Share</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 35%"><font style="font-size: 10pt">Balance at December 31, 2017</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1,222,500</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">0.50-15 </font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">2.91 years </font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1.08</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Options granted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Options exercised</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Options expired</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Balance at June 30, 2018</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,222,500</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">$</font></td> <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">0.50-15 </font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">2.42 years </font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">$</font></td> <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">$</font></td> <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">1.08</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Exercisable at June 30, 2018</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,222,500</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.50-15 </font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2.42 years </font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1.08</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three and six months ended June 31, 2018 the Company recognized $21,645 and $45,400 worth of stock based compensation related to the vesting of its stock options.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common Stock Warrants</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following schedule summarizes the changes in the Company&#8217;s stock warrants:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="6" style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Weighted</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Weighted</font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Warrants Outstanding</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><font style="font-size: 10pt">Average</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><font style="font-size: 10pt">Average</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Number</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Exercise</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Remaining</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Aggregate</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Exercise</font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Of</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Price</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Contractual</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Intrinsic</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Price</font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Shares</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Per Share</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Life</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Value</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Per Share</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 35%"><font style="font-size: 10pt">Balance at December 31, 2017</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">304,200</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">0.40-10 </font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1.19 years </font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">2.63</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Warrants granted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Warrants exercised</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Warrants expired/cancelled</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">400</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">$</font></td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">$</font></td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 10pt">6.00</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Balance at June 30, 2018</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">303,800</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">$</font></td> <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">0.40-10 </font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">0.70 years </font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">$</font></td> <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">$</font></td> <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">2.63</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Exercisable at June 30, 2018</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">303,800</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.40-10 </font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.70 years </font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">2.63</font></td> <td>&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Restricted Stock Units</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following schedule summarizes the changes in the Company&#8217;s restricted stock units:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Weighted</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Number</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Average</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Of</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Grant Date</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Shares</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Fair Value</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%"><font style="font-size: 10pt">Balance at December 31, 2017</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 14%; text-align: right"><font style="font-size: 10pt">5,740,000</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 14%; text-align: right"><font style="font-size: 10pt">0.07</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">RSU&#8217;s granted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">RSU&#8217;s vested</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(1,240,000</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">RSU&#8217;s forfeited</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">$</font></td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Balance at June 30, 2018</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,500,000</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">$</font></td> <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">0.07</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three and the six months ended June 30, 2018 the Company recognized $32,801 and $84,895 worth of expense related to the vesting of its RSU&#8217;s. As of June 30, 2018, the Company had $269,534 worth of expense yet to be recognized for RSU&#8217;s not yet vested.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 8: STOCKHOLDERS&#8217; EQUITY</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common Stock</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ending June 30, 2018 the Company issued 41,146,060 shares of its common stock valued at $376,181 for conversion of convertible debt, 10,000 shares of its common stock valued at $449 for services, 9,666,670 shares of its common stock valued at $3,972,942 for conversions of 966,667 shares of Series A Preferred, and 1,240,000 shares of its common stock valued at $1,240 in the form of Restricted Stock Units.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 9: SUPPLEMENTAL CASH FLOW INFORMATION</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ending June 30, 2018 the Company had the following non-cash investing and financing activities:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 72px; text-align: justify">&#160;</td> <td style="width: 24px; text-align: justify"><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Exchanged $32,279 of accounts payable for a one year, 18% Promissory note. </font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Issued 9,666,670 shares of common stock in exchange for 966,667 shares of Series A Preferred decreasing preferred stock by $3,972,942, increasing common stock by $9,667, and increasing paid in capital by $3,963,275.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Increased common stock and decreased paid in capital by $1,240 due to the vesting of restricted stock units.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">Issued 41,146,060 shares of common stock in exchange for convertible note principal of $197,283 and accrued interest of $3,439, reducing the derivative liability by $271,851.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 10: COMMITMENTS AND CONTINGENCIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is continuing work on many avenues to find the money needed to fund operations and provide sufficient funds needed to bring its product to market. &#160;The Company entered into an agreement in May 2018 to find accredited investors for funding the Company under which it will pay a 5% finders fee of the gross proceeds for any financing made available to the Company plus common stock shares equal to 5% of the aggregate proceeds divided by the price per share of common stock issued in connection with the financing.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 11: SUBSEQUENT EVENTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px; text-align: justify">&#160;</td> <td style="width: 24px; text-align: justify"><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">In July and August 2018, the Company received $13,645 as a loan from a Director.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">In July 2018, the Company issued a six month, 8%, convertible promissory note for $50,000.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">In July and August 2018, the Company issued 255,759,303 shares of common stock in exchange for $418,168 of convertible debt and $17,745 of accrued interest.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify"><font style="font-size: 10pt">&#9679;</font></td> <td style="text-align: justify"><font style="font-size: 10pt">In July 2018, the Company issued 410,160 shares of common stock for 41,016 shares of Series A Preferred.</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated subsequent events through the date of this filing pursuant to ASC Topic 855 and has determined that, except as disclosed herein, there are no additional subsequent events to disclose.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Use of Estimates</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Fair Value of Financial Instruments</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair Value of Financial Instruments, requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of June 30, 2018 and December 31, 2017, the balances reported for cash, prepaid expenses, accounts receivable, accounts payable, and accrued expenses, approximate the fair value because of their short maturities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 36pt; text-align: justify">Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company measures certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis were calculated using the Black-Scholes pricing model and are as follows at June 30, 2018:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">June 30, 2018</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Total</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Level 1</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Level 2</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Level 3</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Liabilities:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%; padding-bottom: 1.5pt"><font style="font-size: 10pt">Derivative Liability</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">5,232,274</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">5,232,274</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total Liabilities Measured at Fair Value</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,232,274</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,232,274</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Reclassifications</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain account balances from prior periods have been reclassified in the current period financial statements so as to conform to current period classifications.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Recent Accounting Pronouncements</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There are no recently issued accounting pronouncements that the Company has not yet adopted that they believe are applicable or would have a material impact on the financial statements of the Company.</p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company measures certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis were calculated using the Black-Scholes pricing model and are as follows at June 30, 2018:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">June 30, 2018</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Total</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Level 1</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Level 2</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Level 3</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Liabilities:</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 48%; padding-bottom: 1.5pt"><font style="font-size: 10pt">Derivative Liability</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">5,232,274</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="width: 9%; border-bottom: black 1.5pt solid; text-align: right">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td> <td style="width: 1%; border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">5,232,274</font></td> <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total Liabilities Measured at Fair Value</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,232,274</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,232,274</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fixed assets consist of the following at June 30, 2018 and December 31, 2017:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">June 30, </font><br /> <font style="font-size: 10pt">2018</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31, </font><br /> <font style="font-size: 10pt">2017</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font-size: 10pt">Production equipment</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">15,182</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">15,182</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less accumulated depreciation</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(15,182</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(15,182</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2018 and December 31, 2017 the Company had the following convertible notes outstanding:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">June 30, 2018</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31, 2017</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Principal</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(net)</p></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Accrued Interest</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Principal</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(net)</p></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Accrued Interest</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%"><font style="font-size: 10pt">July and August 2012 $1,060,000 Notes convertible into common stock at $4.60 per share, 12% interest, due December 2013 and January 2014</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">45,000</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">31,888</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">45,000</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">29,218</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">May through October 2015 $605,000 Notes convertible into preferred stock at $1 per share, 8-10% interest, due September 30, 2015</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">17,341</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">17,341</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">October through December 2015 $613,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016, net of debt discount of $0 and $0, respectively</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,953</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">5,953</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">January through March 2016 $345,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">696</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">696</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">May 2017 $2,332,305 Notes convertible into common stock after April 15, 2018 at a 45% discount to lowest trade price for previous 30 days ($0.0017 at June 30, 2018), 7.5% interest, due May 2018 therefore in default as of June 30, 2018, net of debt discounts of $0 and $544,845, respectively</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2,332,305</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">200,087</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,833,310</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">178,304</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">May 2017 $530,539 Notes convertible into common stock after April 15, 2018 at a 45% discount to lowest trade price for previous 30 days ($0.0017 at June 30, 2018), 7.5% interest, due May 2018, net of debt discounts of $0 and $147,335, respectively</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">530,539</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">58,890</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">500,703</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">52,831</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">May 2017 $76,379 Notes convertible after April 15, 2018 into common stock at a 45% discount to lowest trade price for previous 30 days ($0.0017 at June 30, 2018), 7.5% interest, due May 2018 therefore in default as of June 30, 2018, net of debt discounts of $0 and $25,085, respectively</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">76,379</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">16,724</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">85,227</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">15,773</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">November 2017 $166,666 Note convertible at maturity at a 50% discount to lowest trade price for previous 25 days ($0.0015 at June 30, 2018), with a one-time interest charge of 10%, due April 15, 2018 therefore in default as of June 30, 2018, net of debt discounts of $0 and $74,662, respectively</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">166,666</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">96,667</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">92,004</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">16,667</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Penalties on notes in default</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">7,918</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">7,028</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total Convertible Notes Payable, Net</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,158,807</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">428,246</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,563,272</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">316,784</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following schedule summarizes the changes in the Company&#8217;s stock options:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Weighted</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Weighted</font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Options Outstanding</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><font style="font-size: 10pt">Average</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><font style="font-size: 10pt">Average</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Number</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Exercise</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Remaining</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Aggregate</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Exercise</font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Of</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Price</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Contractual</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Intrinsic</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Price</font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Shares</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Per Share</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Life</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Value</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Per Share</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 35%"><font style="font-size: 10pt">Balance at December 31, 2017</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1,222,500</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">0.50-15 </font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">2.91 years </font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1.08</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Options granted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Options exercised</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt"><font style="font-size: 10pt">Options expired</font></td> <td>&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Balance at June 30, 2018</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,222,500</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">$</font></td> <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">0.50-15 </font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">2.42 years </font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">$</font></td> <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">$</font></td> <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">1.08</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Exercisable at June 30, 2018</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1,222,500</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.50-15 </font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">2.42 years </font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1.08</font></td> <td>&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following schedule summarizes the changes in the Company&#8217;s stock warrants:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="6" style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Weighted</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Weighted</font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Warrants Outstanding</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><font style="font-size: 10pt">Average</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><font style="font-size: 10pt">Average</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Number</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Exercise</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Remaining</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Aggregate</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Exercise</font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Of</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Price</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Contractual</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Intrinsic</font></td> <td style="text-align: center">&#160;</td> <td style="text-align: center">&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Price</font></td> <td style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Shares</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Per Share</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Life</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Value</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Per Share</font></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 35%"><font style="font-size: 10pt">Balance at December 31, 2017</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">304,200</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">0.40-10 </font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1.19 years </font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">2.63</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Warrants granted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Warrants exercised</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Warrants expired/cancelled</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">400</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">$</font></td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">$</font></td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 10pt">6.00</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Balance at June 30, 2018</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">303,800</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">$</font></td> <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">0.40-10 </font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">0.70 years </font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">$</font></td> <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">$</font></td> <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">2.63</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Exercisable at June 30, 2018</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">303,800</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.40-10 </font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.70 years </font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">2.63</font></td> <td>&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following schedule summarizes the changes in the Company&#8217;s restricted stock units:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Weighted</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Number</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Average</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Of</font></td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center"><font style="font-size: 10pt">Grant Date</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Shares</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Fair Value</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td colspan="2" style="text-align: center">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 66%"><font style="font-size: 10pt">Balance at December 31, 2017</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 14%; text-align: right"><font style="font-size: 10pt">5,740,000</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 14%; text-align: right"><font style="font-size: 10pt">0.07</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">RSU&#8217;s granted</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">RSU&#8217;s vested</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(1,240,000</font></td> <td><font style="font-size: 10pt">)</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">RSU&#8217;s forfeited</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">$</font></td> <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 10pt">-</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right">&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Balance at June 30, 2018</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,500,000</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">$</font></td> <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">0.07</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 1500000 966667 9666670 3972942 4054 5232274 5232274 5232274 4636517 57297 82572 269534 1240 197283 50000 3439 271851 101631 383771 383771 83280 32308 0 4500 84895 32801 966667 41016 41146060 0.45 0.45 0.45 0.50 30 30 30 25 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 6: DERIVATIVE LIABILITY</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2018 the Company had certain convertible notes become convertible on a set date at variable conversion rates. Upon becoming convertible the Company bifurcated the embedded conversion feature and recorded a derivative liability at fair value with the offsetting entry recorded in the statement of operations. The activity in the derivative liability account during the six months ended June 30, 2018 is summarized as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Derivative Liability at December 31, 2017</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 82%"><font style="font-size: 10pt">Derivative Liability Recorded</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: right"><font style="font-size: 10pt">4,636,517</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Elimination of Liability on Conversion</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(271,851</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Change in Fair Value</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">867,608</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Derivative Liability at June 30, 2018</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,232,274</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company uses the Black-Scholes pricing model to estimate fair value for those instruments convertible into common stock at inception, at conversion date, and at each reporting date.&#160;&#160;During the six months ended June 30, 2018 the Company used the following assumptions in their Black-Scholes model:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Risk-free interest rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1.62% - 2.35</font></td> <td><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Expected life in years</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.12 - 1.10</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%"><font style="font-size: 10pt">Dividend yield</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: right"><font style="font-size: 10pt">0</font></td> <td style="width: 1%"><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Expected volatility</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">174.46% - 221.03</font></td> <td><font style="font-size: 10pt">%</font></td></tr> </table> <p style="margin: 0pt"></p> 5232274 4636517 867608 0.0162 0.0235 0.00 1.7446 2.2103 P1M13D P1Y1M6D The Company under which it will pay a 5% finders fee of the gross proceeds for any financing made available to the Company plus common stock shares equal to 5% of the aggregate proceeds divided by the price per share of common stock issued in connection with the financing. -271851 <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">During the six months ended June 30, 2018 the Company used the following assumptions in their Black-Scholes model:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Risk-free interest rate</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">1.62% - 2.35</font></td> <td><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Expected life in years</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">0.12 - 1.10</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%"><font style="font-size: 10pt">Dividend yield</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: right"><font style="font-size: 10pt">0</font></td> <td style="width: 1%"><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Expected volatility</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">174.46% - 221.03</font></td> <td><font style="font-size: 10pt">%</font></td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The activity in the derivative liability account during the six months ended June 30, 2018 is summarized as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Derivative Liability at December 31, 2017</font></td> <td>&#160;</td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 82%"><font style="font-size: 10pt">Derivative Liability Recorded</font></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 15%; text-align: right"><font style="font-size: 10pt">4,636,517</font></td> <td style="width: 1%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Elimination of Liability on Conversion</font></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 10pt">(271,851</font></td> <td><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Change in Fair Value</font></td> <td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: black 1.5pt solid">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">867,608</font></td> <td style="padding-bottom: 1.5pt">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Derivative Liability at June 30, 2018</font></td> <td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,232,274</font></td> <td style="padding-bottom: 2.5pt">&#160;</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; background-color: white"></p> <p style="margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Derivative Liabilities</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates its convertible debt, options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with Accounting Standards Codification topic 815, Accounting for Derivative Instruments and Hedging Activities (&#8220;ASC 815&#8221;) as well as related interpretations of this standard and Accounting Standards Update 2017-11, which was adopted by the Company effective January 1, 2018. In accordance with this standard, derivative instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair values with gains or losses recognized in earnings. Embedded derivatives that are not clearly and closely related to the host contract are bifurcated and are recognized at fair value with changes in fair value recognized as either a gain or loss in earnings.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The result of this accounting treatment is that the fair value of the derivative instrument is marked-to-market each balance sheet date and with the change in fair value recognized in the statement of operations as other income or expense.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation and then that the related fair value is removed from the books. Gains or losses on debt extinguishment are recognized in the statement of operations upon conversion, exercise or cancellation of a derivative instrument after any shares issued in such a transaction are recorded at market value. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Instruments that become a derivative after inception are recognized as a derivative on the date they become a derivative with the offsetting entry recorded in earnings.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determines the fair value of derivative instruments and hybrid instruments, considering all of the rights and obligations of each instrument, based on available market data using the Black-Scholes model, adjusted for the effect of dilution, because it embodies all of the requisite assumptions (including trading volatility, estimated terms, dilution and risk-free rates) necessary to fair value these instruments. For instruments in default with no remaining time to maturity the Company uses a one-year term for their years to maturity estimate unless a sooner conversion date can be estimated or is known. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques (such as Black-Scholes model) are highly volatile and sensitive to changes in the trading market price of our common stock.</p> EX-101.SCH 6 rdgl-20180630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statements of Cash Flow (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Basis of Presentation and Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Fixed Assets link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Convertible Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Derivative Liability link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Common Stock Options and Warrants link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Supplemental Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Fixed Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Convertible Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Derivative Liability (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Common Stock Options and Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Fixed Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Fixed Assets - Schedule of Fixed Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Derivative Liability - Schedule of Derivative Liability Account Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Derivative Liability - Schedule of Assumptions for Fair Value Determination (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Common Stock Options and Warrants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Common Stock Options and Warrants - Schedule of Changes in Stock Option (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Common Stock Options and Warrants - Schedule of Changes in Stock Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Common Stock Options and Warrants - Schedule of Changes in Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Supplemental Cash Flow Information (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 rdgl-20180630_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 rdgl-20180630_def.xml XBRL DEFINITION FILE EX-101.LAB 9 rdgl-20180630_lab.xml XBRL LABEL FILE PropertyPlantAndEquipmentByType [Axis] Production Equipment [Member] Debt Instrument [Axis] Convertible Notes Payable One [Member] Convertible Notes Payable Two [Member] Convertible Notes Payable Three [Member] Convertible Notes Payable Four [Member] Convertible Notes Payable Five [Member] Convertible Notes Payable Six [Member] Convertible Notes Payable Seven [Member] Award Type [Axis] Stock Options Range [Axis] Minimum [Member] Maximum [Member] Warrants [Member] Fair Value, Hierarchy [Axis] Level 1 [Member] Level 2 [Member] Level 3 [Member] Class of Stock [Axis] Series A Preferred Stock [Member] Common Stock [Member] Convertible Notes Payable Eight [Member] Restricted Stock Units [Member] Related Party [Axis] Director and Major Stockholder [Member] Title of Individual [Axis] CFO [Member] Shareholder and Director [Member] CEO [Member] Common Stock Option [Member] Employee [Member] Related Party Note [Member] Promissory Note [Member] Measurement Frequency [Axis] Fair Value, Measurements, Recurring [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Measurement Input Type [Axis] Risk-free Interest Rate [Member] Expected Term [Member] Dividend Yield [Member] Expected Volatility [Member] 8% Convertible Promissory Note [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current assets: Cash Prepaid expenses Total current assets Fixed assets, net of accumulated depreciation Other assets: Deposits Total other assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable and accrued expenses Related party payables Accrued interest payable Payroll liabilities payable Derivative liability Convertible notes payable, net Loan from shareholder Notes payable Related party promissory note Total current liabilities Total liabilities Commitments and contingencies Stockholders' equity (deficit): Preferred stock, $.001 par value, 20,000,000 shares authorized; 2,811,955 and 3,778,622 shares issued and outstanding, respectively Paid in capital, preferred stock Common stock, $.001 par value; 2,000,000,000 shares authorized; 117,757,943 and 65,695,213 shares issued and outstanding, respectively Paid in capital Accumulated deficit Total stockholders' equity (deficit) Total liabilities and stockholders' equity (deficit) Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenues Operating expenses Sales and marketing expenses Depreciation and amortization Professional fees Reserved stock units granted Stock options granted Payroll expenses Research and development General and administrative expenses Total operating expenses Operating loss Non-operating income (expense) Interest expense Net gain on sale of assets Grants received Net gain (loss) on debt extinguishment Gain (loss) on derivative liability Non-operating income (expense), net Income (Loss) before Income Taxes Income Tax Provision Net Income (Loss) Basic and Diluted Income (Loss) per Common Share Basic and Diluted Weighted average common shares outstanding Statement of Cash Flows [Abstract] CASH FLOW FROM OPERATING ACTIVITIES: Net Loss Adjustments to reconcile net loss to net cash used by operating activities: Depreciation of fixed assets Amortization of convertible debt discount Gain on sale of assets Common stock issued for services Stock options and warrants issued for services Reserved stock units issued for services New derivatives recorded as loan fees (Gain) loss on derivative liability (Gain) loss on settlement of debt Changes in operating assets and liabilities: Prepaid expenses Accounts payable Accounts payable from related parties Payroll liabilities Accrued interest Net cash used by operating activities CASH FLOWS FROM INVESTING ACTIVITIES Sale of fixed assets Net cash from investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Payments made for loan fees Proceeds from shareholder advances Proceeds from related party advances Proceeds from convertible debt Net cash provided by financing activities Net increase (decrease) in cash Cash, beginning of period CASH, END OF PERIOD Supplemental disclosures of cash flow information: Cash paid for interest Cash paid for income taxes Accounting Policies [Abstract] Basis of Presentation and Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements [Abstract] Going Concern Property, Plant and Equipment [Abstract] Fixed Assets Related Party Transactions [Abstract] Related Party Transactions Debt Disclosure [Abstract] Convertible Notes Payable Notes to Financial Statements Derivative Liability Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Common Stock Options and Warrants Equity [Abstract] Stockholders' Equity Supplemental Cash Flow Elements [Abstract] Supplemental Cash Flow Information Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events Use of Estimates Fair Value of Financial Instruments Derivative Liabilities Reclassifications Recent Accounting Pronouncements Schedule of Fair Value of Financial Instruments Schedule of Fixed Assets Schedule of Convertible Notes Payable Schedule of Derivative Liability Account Activity Schedule of Assumptions for Fair Value Determination Schedule of Changes in Stock Option Schedule of Changes in Stock Warrants Schedule of Changes in Restricted Stock Units Statement [Table] Statement [Line Items] Fair Value Hierarchy and NAV [Axis] Derivative Liability Total Liabilities Measured at Fair Value Requires funding to maintain current operating activities Capital Cash on hand Depreciation expense Property, Plant and Equipment, Type [Axis] Production equipment Less accumulated depreciation Net fixed assets Accrued interest payable Related party transaction accrued interest rate Note maturity date Note maturity date, description Related party note Number of shares issued, shares Accrued payroll Accrued payable Wages valued Payment of rent Expire Date Rental expense Principal (net) Accrued Interest Penalties on notes past due principal (net) Debt principal amount Debt conversion price per share Debt interest rate Debt maturity date description Debt discount Debt instrument trading percentage Debt trading days Derivative Liability, Beginning balance Derivative Liability Recorded Elimination of Liability on Conversion Change in Fair Value Derivative Liability, Ending balance Fair value assumptions, percentage Fair value assumption, expected term Stock based compensation Restricted stock expense Stock options expense yet to be recognized Number of Shares Options Outstanding Beginning Balance Number of Options granted Number of Options exercised Number of Options expired Number of Shares Options Outstanding Ending Balance Number of Shares Options Exercisable Weighted Average Exercise Price Outstanding Beginning Balance Weighted Average Exercise Price granted Weighted Average Exercise Price exercised Weighted Average Exercise Price expired Weighted Average Exercise Price Outstanding Ending Balance Exercise Price Per Share Exercisable Weighted Average Remaining Contractual Life (in years) Outstanding, Beginning Weighted Average Remaining Contractual Life (in years) Outstanding, Ending Weighted Average Remaining Contractual Life (in years) Exercisable Aggregate Intrinsic Value Outstanding Beginning Aggregate Intrinsic Value Outstanding Ending Aggregate Intrinsic Value Exercisable Weighted Average Exercise Price Per Share Outstanding Beginning Weighted Average Exercise Price Per Share Options granted Weighted Average Exercise Price Per Share Options exercised Weighted Average Exercise Price Per Share Options expired Weighted Average Exercise Price Per Share Outstanding Ending Weighted Average Exercise Price Per Share Exercisable Number of Shares, Warrants Outstanding Beginning Number of Shares, Warrants granted Number of Shares, Warrants exercised Number of Shares, Warrants expired/cancelled Number of Shares, Warrants Outstanding Ending Number of Shares, Warrants Exercisable Ending Weighted Average Exercise Price Outstanding Exercise Price Per Share Warrants granted Exercise Price Per Share Warrants exercised Exercise Price Per Share Warrants expired/cancelled Weighted Average Exercise Price Outstanding Exercise Price Per Share Exercisable Weighted Average Remaining Contractual Life Warrants Outstanding, Beginning Weighted Average Remaining Contractual Life Warrants Outstanding Ending Weighted Average Remaining Contractual Life Warrants Exercisable Weighted Average Exercise Price Per Share Exercise Price Warrants Beginning Weighted Average Exercise Price Per Share Exercise Price Warrants granted Weighted Average Exercise Price Per Share Exercise Price Warrants exercised Weighted Average Exercise Price Per Share Exercise Price Warrants expired/cancelled Weighted Average Exercise Price Per Share Exercise Price Warrants Ending Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable Number of Shares, RSU's Outstanding Beginning Number of Shares, RSU's Granted Number of Shares, RSU's Vested Number of Shares, RSU's Forfeited Number of Shares, RSU's Outstanding Ending Weighted Average Grant Date Fair Value, RSU's Outstanding Beginning Weighted Average Grant Date Fair Value, RSU's Granted Weighted Average Grant Date Fair Value, RSU's Vested Weighted Average Grant Date Fair Value, RSU's Forfeited Weighted Average Grant Date Fair Value, RSU's Outstanding Ending Number of shares issued for conversion of convertible debt Number of shares issued for conversion of convertible debt, amount Common stock issued for services Common stock issued for services, value Number of common shares issued for conversion of preferred stock Number of common shares issued for conversion of preferred stock, value Number of stock issued during period Value of stock issued during period Exchanged accounts payable Issued shares of common stock in exchange for preferred stock Number of shares exchanged Decrease in preferred stock Increase in common stock Increase in additional paid in capital Increased common stock and decreased in capital Number of shares issued to exchange convertible note principal Convertible notes payable Accrued interest Reducing derivative liability Investors funding, description Director [Member] Proceeds from loan Convertible promissory note Common stock issued for conversion of debt, shares Debt conversion of convertible debt Accrued interest Conversion of stock, shares Conversion of stock, number of shares converted CEO [Member] CFO [Member] Common Stock Option [Member] Consultant [Member] Convertible Notes Payable Eight [Member] Convertible Notes Payable Five [Member] Convertible Notes Payable Four [Member] Convertible Notes Payable Nine [Member] Convertible Notes Payable One [Member] Convertible Notes Payable Seven [Member] Convertible Notes Payable Six [Member] Convertible Notes Payable Ten [Member] Convertible Notes Payable Three [Member] Convertible Notes Payable Two [Member] Decrease in preferred stock. Director and Major Stockholder [Member] Employee [Member] Weighted Average Exercise Price Per Share Options expired. Weighted Average Exercise Price Per Share Exercise Price Warrants Expired/cancelled. Weighted Average Exercise Price Per Share Exercise Price Warrants Granted. Weighted Average Exercise Price Per Share Exercise Price Warrants Beginning Ending. Increase in common stock. Loan from shareholder. Penalties on notes past due principal (net). Promissory Note [Member] Related Party Note [Member] Reserved stock units granted. Restricted Stock Units [Member] Series A Convertible Preferred Stock [Member] The weighted average fair value at exercisable date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Share based compensation arrangement by share based payment award non-option equity instruments vested. Number of Shares, Exercisable, end of period. weighted average grant date fair value, RSU's outstanding beginning and ending. Weighted Average Exercise Price Exercisable. Share-based compensation arrangements by share-based payment award, non-options, forfeited in period, weighted average exercise price. Share-based compensation arrangements by share-based payment award, non-options, grants in period, weighted average exercise price. Share-based compensation arrangements by share-based payment award, non-options, vested in period, weighted average exercise price. Shareholder and Director [Member] Stock options and warrants issued for services. Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable. Weighted Average Exercise Price Per Share Exercise Price Warrants Exercised. Weighted Average Exercise Price Per Share Options Exercised. Weighted Average Exercise Price Per Share Options granted. Weighted Average Remaining Contractual Life In Years Outstanding Beginning. Weighted Average Remaining Contractual Life (in years) Warrants Outstanding, Beginning. Total Liabilities Measured at Fair Value. New derivatives recorded as loan fees. Increased common stock and decreased in capital. Accrued interest. Number of shares issued to exchange convertible note principal. Derivative Liability Recorded. Fair value assumption, expected term. Fair value assumptions, percentage. 8% Convertible Promissory Note [Member] Investors funding, description. Elimination of Liability on Conversion. Assets, Current Other Assets, Noncurrent Assets Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Expense Nonoperating Income (Expense) StockOptionsAndWarrantsIssuedForServices Debtor Reorganization Items, Gain (Loss) on Settlement of Other Claims, Net Increase (Decrease) in Prepaid Expense Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Investing Activities Payments of Loan Costs Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Cash and Cash Equivalents, at Carrying Value Derivative Asset, Fair Value, Gross Liability Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Derivative Liability, Fair Value, Gross Liability Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number ExercisePriceMinimum Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value ExercisePriceMinimum [Default Label] Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Excercise Price, Warrants Granted, Minimum Stock Issued During Period, Shares, Issued for Services AccruedInterestNonCashTransactions EX-101.PRE 10 rdgl-20180630_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
 6 Months Ended
Jun. 30, 2018
Aug. 16, 2018
Document And Entity Information    
Entity Registrant Name VIVOS INC  
Entity Central Index Key 0001449349  
Document Type 10-Q  
Document Period End Date Jun. 30, 2018  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   373,927,406
Trading Symbol RDGL  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2018  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Balance Sheets - USD ($)
Jun. 30, 2018
Dec. 31, 2017
Current assets:    
Cash $ 8,317
Prepaid expenses 7,492 6,711
Total current assets 7,492 15,028
Fixed assets, net of accumulated depreciation
Other assets:    
Deposits 669 669
Total other assets 669 669
Total assets 8,161 15,697
Current liabilities:    
Accounts payable and accrued expenses 1,040,275 840,972
Related party payables 82,572 57,297
Accrued interest payable 480,436 347,069
Payroll liabilities payable 216,436 85,786
Derivative liability 5,232,274
Convertible notes payable, net 3,158,807 2,563,272
Loan from shareholder 50,000
Notes payable 32,279
Related party promissory note 383,771 383,771
Total current liabilities 10,676,850 4,278,167
Total liabilities 10,676,850 4,278,167
Commitments and contingencies
Stockholders' equity (deficit):    
Preferred stock, $.001 par value, 20,000,000 shares authorized; 2,811,955 and 3,778,622 shares issued and outstanding, respectively 2,811 3,779
Paid in capital, preferred stock 9,575,805 13,547,780
Common stock, $.001 par value; 2,000,000,000 shares authorized; 117,757,943 and 65,695,213 shares issued and outstanding, respectively 117,758 65,695
Paid in capital 50,836,259 46,408,443
Accumulated deficit (71,201,322) (64,288,167)
Total stockholders' equity (deficit) (10,668,689) (4,262,470)
Total liabilities and stockholders' equity (deficit) $ 8,161 $ 15,697
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Balance Sheets (Parenthetical) - $ / shares
Jun. 30, 2018
Dec. 31, 2017
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 20,000,000 20,000,000
Preferred stock, shares issued 2,811,955 3,778,622
Preferred stock, shares outstanding 2,811,955 3,778,622
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 2,000,000,000 2,000,000,000
Common stock, shares issued 117,757,943 65,695,213
Common stock, shares outstanding 117,757,943 65,695,213
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Income Statement [Abstract]        
Revenues $ 4,054
Operating expenses        
Sales and marketing expenses 2,950 15,251 12,950 41,249
Depreciation and amortization 733 1,473
Professional fees 145,220 295,544 215,278 430,148
Reserved stock units granted 32,801 84,895
Stock options granted 21,645 27,059 45,400 55,299
Payroll expenses 82,200 181,494 161,070 286,275
Research and development 41,766 80,523 74,580 113,409
General and administrative expenses 15,318 18,567 34,421 60,087
Total operating expenses 341,900 619,171 628,594 987,940
Operating loss (341,900) (619,171) (628,594) (983,886)
Non-operating income (expense)        
Interest expense (4,934,066) (781,139) (5,566,140) (1,309,090)
Net gain on sale of assets 2,800
Grants received 17,583
Net gain (loss) on debt extinguishment 131,604 (201,574) 131,604 (53,863)
Gain (loss) on derivative liability (867,608) 83,089 (867,608) 408,479
Non-operating income (expense), net (5,670,070) (899,624) (6,284,561) (951,674)
Income (Loss) before Income Taxes (6,011,970) (1,518,795) (6,913,155) (1,935,560)
Income Tax Provision
Net Income (Loss) $ (6,011,970) $ (1,518,795) $ (6,913,155) $ (1,935,560)
Basic and Diluted Income (Loss) per Common Share $ (0.0681) $ (0.0327) $ (0.0836) $ (0.0457)
Basic and Diluted Weighted average common shares outstanding 88,308,304 46,454,069 78,103,383 42,375,108
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Statements of Cash Flow (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
CASH FLOW FROM OPERATING ACTIVITIES:    
Net Loss $ (6,913,155) $ (1,935,560)
Adjustments to reconcile net loss to net cash used by operating activities:    
Depreciation of fixed assets 1,473
Amortization of convertible debt discount 791,938 957,499
Gain on sale of assets (2,800)
Common stock issued for services 449 171,090
Stock options and warrants issued for services 45,400 55,299
Reserved stock units issued for services 84,895
New derivatives recorded as loan fees 4,636,517
(Gain) loss on derivative liability 867,608 (408,479)
(Gain) loss on settlement of debt (131,604) 53,863
Changes in operating assets and liabilities:    
Prepaid expenses (781) 5,142
Accounts payable 266,795 39,949
Accounts payable from related parties (13,284) (4,675)
Payroll liabilities 130,650 (60,212)
Accrued interest 137,696 350,468
Net cash used by operating activities (96,876) (776,944)
CASH FLOWS FROM INVESTING ACTIVITIES    
Sale of fixed assets 2,800
Net cash from investing activities 2,800
CASH FLOWS FROM FINANCING ACTIVITIES:    
Payments made for loan fees (101,631)
Proceeds from shareholder advances 50,000 137,000
Proceeds from related party advances 38,559
Proceeds from convertible debt 1,080,334
Net cash provided by financing activities 88,559 1,115,703
Net increase (decrease) in cash (8,317) 341,560
Cash, beginning of period 8,317 27,889
CASH, END OF PERIOD 369,449
Supplemental disclosures of cash flow information:    
Cash paid for interest
Cash paid for income taxes
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basis of Presentation and Significant Accounting Policies
 6 Months Ended
Jun. 30, 2018
Accounting Policies [Abstract]  
Basis of Presentation and Significant Accounting Policies

NOTE 1: BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

 

The accompanying condensed financial statements of Vivos Inc. (the “Company”) have been prepared without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and disclosures required by accounting principles generally accepted in the United States have been condensed or omitted pursuant to such rules and regulations. These condensed financial statements reflect all adjustments that, in the opinion of management, are necessary to present fairly the results of operations of the Company for the period presented. The results of operations for the six months ended June 30, 2018, are not necessarily indicative of the results that may be expected for any future period or the fiscal year ending December 31, 2018 and should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission on April 2, 2018.

 

In April of 2017, the Company filed a Certificate of Merger with the Delaware Division of Corporations in order to merge the Company’s wholly-owned subsidiary, IsoPet Solutions Corporation, with and into the Company. The Company therefore no longer prepares Consolidated Financial Statements.

 

Use of Estimates

 

The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Fair Value of Financial Instruments

 

Fair Value of Financial Instruments, requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of June 30, 2018 and December 31, 2017, the balances reported for cash, prepaid expenses, accounts payable, and accrued expenses, approximate the fair value because of their short maturities.

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:

 

Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;

 

Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

 

Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

The Company measures certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis were calculated using the Black-Scholes pricing model and are as follows at June 30, 2018:

 

June 30, 2018                        
                         
    Total     Level 1     Level 2     Level 3  
Liabilities:                                
Derivative Liability   $ 5,232,274     $       $       $ 5,232,274  
Total Liabilities Measured at Fair Value   $ 5,232,274     $ -     $ -     $ 5,232,274  

 

Derivative Liabilities

 

The Company evaluates its convertible debt, options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with Accounting Standards Codification topic 815, Accounting for Derivative Instruments and Hedging Activities (“ASC 815”) as well as related interpretations of this standard and Accounting Standards Update 2017-11, which was adopted by the Company effective January 1, 2018. In accordance with this standard, derivative instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair values with gains or losses recognized in earnings. Embedded derivatives that are not clearly and closely related to the host contract are bifurcated and are recognized at fair value with changes in fair value recognized as either a gain or loss in earnings.

 

The result of this accounting treatment is that the fair value of the derivative instrument is marked-to-market each balance sheet date and with the change in fair value recognized in the statement of operations as other income or expense.

 

Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation and then that the related fair value is removed from the books. Gains or losses on debt extinguishment are recognized in the statement of operations upon conversion, exercise or cancellation of a derivative instrument after any shares issued in such a transaction are recorded at market value. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Instruments that become a derivative after inception are recognized as a derivative on the date they become a derivative with the offsetting entry recorded in earnings.

 

The Company determines the fair value of derivative instruments and hybrid instruments, considering all of the rights and obligations of each instrument, based on available market data using the Black-Scholes model, adjusted for the effect of dilution, because it embodies all of the requisite assumptions (including trading volatility, estimated terms, dilution and risk-free rates) necessary to fair value these instruments. For instruments in default with no remaining time to maturity the Company uses a one-year term for their years to maturity estimate unless a sooner conversion date can be estimated or is known. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques (such as Black-Scholes model) are highly volatile and sensitive to changes in the trading market price of our common stock.

 

Reclassifications

 

Certain account balances from prior periods have been reclassified in the current period financial statements so as to conform to current period classifications.

 

Recent Accounting Pronouncements

 

There are no recently issued accounting pronouncements that the Company has not yet adopted that they believe are applicable or would have a material impact on the financial statements of the Company.
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Going Concern
 6 Months Ended
Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Going Concern

NOTE 2: GOING CONCERN

 

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements, the Company has suffered recurring losses and used significant cash in support of its operating activities and the Company’s cash position is not sufficient to support the Company’s operations. Research and development of the Company’s brachytherapy product line has been funded with proceeds from the sale of equity and debt securities as well as a series of grants. The Company requires funding of approximately $1.5 million annually to maintain current operating activities. Over the next 12 to 24 months, the Company believes it will cost approximately $5.0 million to $10.0 million to fund: (1) the FDA approval process and initial deployment of the brachytherapy products, and (2) initiate regulatory approval processes outside of the United States. The continued deployment of the brachytherapy products and a worldwide regulatory approval effort will require additional resources and personnel. The principal variables in the timing and amount of spending for the brachytherapy products in the next 12 to 24 months will be the FDA’s classification of the Company’s brachytherapy products as Class II or Class III devices (or otherwise) and any requirements for additional studies which may possibly include clinical studies. Thereafter, the principal variables in the amount of the Company’s spending and its financing requirements would be the timing of any approvals and the nature of the Company’s arrangements with third parties for manufacturing, sales, distribution and licensing of those products and the products’ success in the U.S. and elsewhere. The Company intends to fund its activities through strategic transactions such as licensing and partnership agreements or additional capital raises.

 

Following receipt of required regulatory approvals and financing, in the U.S., the Company intends to outsource material aspects of manufacturing, distribution, sales and marketing. Outside of the U.S., the Company intends to pursue licensing arrangements and/or partnerships to facilitate its global commercialization strategy.

 

In the longer-term, subject to the Company receiving adequate funding, regulatory approval for RadioGel™ and other brachytherapy products, and thereafter being able to successfully commercialize its brachytherapy products, the Company intends to consider resuming research efforts with respect to other products and technologies intended to help improve the diagnosis and treatment of cancer and other illnesses

 

Based on the Company’s financial history since inception, its auditor has expressed substantial doubt as to the Company’s ability to continue as a going concern. The Company has limited revenue, nominal cash, and has accumulated deficits since inception. If the Company cannot obtain sufficient additional capital, the Company will be required to delay the implementation of its business strategy and may not be able to continue operations.

 

As of June 30, 2018, the Company has no cash. There are currently commitments to vendors for products and services purchased, plus, the employment agreements of the CEO and CFO of the Company that will necessitate liquidation of the Company if it is unable to raise additional capital. The current level of cash is not enough to cover the fixed and variable obligations of the Company.

 

Assuming the Company is successful in the Company’s sales/development effort, it believes that it will be able to raise additional funds through strategic agreements or the sale of the Company’s stock to either current or new stockholders. There is no guarantee that the Company will be able to raise additional funds or to do so at an advantageous price.

 

The financial statements do not include any adjustments relating to the recoverability and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to generate sufficient cash flow to meet its obligations on a timely basis and ultimately to attain profitability. The Company plans to seek additional funding to maintain its operations through debt and equity financing and to improve operating performance through a focus on strategic products and increased efficiencies in business processes and improvements to the cost structure. There is no assurance that the Company will be successful in its efforts to raise additional working capital or achieve profitable operations. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fixed Assets
 6 Months Ended
Jun. 30, 2018
Property, Plant and Equipment [Abstract]  
Fixed Assets

NOTE 3: FIXED ASSETS

 

Fixed assets consist of the following at June 30, 2018 and December 31, 2017:

 

    June 30,
2018		     December 31,
2017		  
Production equipment   $ 15,182     $ 15,182  
Less accumulated depreciation     (15,182 )     (15,182 )
    $ -     $ -  

 

Depreciation expense for the above fixed assets for the three months ended June 30, 2018 and 2017, respectively, was $0 and $733 and for the six months ended June 30, 2018 and 2017, respectively, was $0 and $1,473.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Transactions
 6 Months Ended
Jun. 30, 2018
Related Party Transactions [Abstract]  
Related Party Transactions

NOTE 4: RELATED PARTY TRANSACTIONS

 

Related Party Convertible Notes Payable

 

In March 2017, the Company combined Outstanding Notes owed to a director and major stockholder, along with $51,576 of accrued interest payable, into one promissory note (the “Related Party Note”). The Related Party Note accrues interest at a rate of 10% and was due and payable on December 31, 2017. The note holder agreed to an extension of the due date until May 9, 2018. As of June 30, 2018 and December 31, 2017 the balance of the Related Party Note was $383,771 and $383,771, respectively, and the accrued interest payable on the Related Party Note was $48,261 and $29,230, respectively.

 

Related Party Payables

 

The Company periodically receives advances for operating funds from related parties or has related parties make payments on the Company’s behalf. As a result of these activities the Company had related party payables of $82,572 and $57,297 as of June 30, 2018 and December 31, 2017, respectively.

 

Preferred Shares Issued to Officers

 

During 2017, the Company issued 100,000 shares of its Series A Preferred to its CEO, in exchange for $32,308 of accrued payroll, $67,692 of accounts payable, and wages valued at $199,690.

 

During 2017, the Company issued 83,279 shares of its Series A Preferred to its CFO, in exchange for $83,280 of accrued payroll and wages valued at $166,299.

 

Rent Expenses

 

The Company was renting office space from a significant shareholder and director of the Company on a month-to-month basis with a monthly payment of $1,500. This rental agreement was terminated as of April 1, 2017.

 

Rental expense was $0 and $4,500 for each of the three months ended June 30, 2018 and 2017 and is recorded in general and administrative expense.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Convertible Notes Payable
 6 Months Ended
Jun. 30, 2018
Debt Disclosure [Abstract]  
Convertible Notes Payable

NOTE 5: CONVERTIBLE NOTES PAYABLE

 

As of June 30, 2018 and December 31, 2017 the Company had the following convertible notes outstanding:

 

    June 30, 2018     December 31, 2017  
   

Principal

(net)

     Accrued Interest    

Principal

(net)

     Accrued Interest  
July and August 2012 $1,060,000 Notes convertible into common stock at $4.60 per share, 12% interest, due December 2013 and January 2014   $ 45,000     $ 31,888     $ 45,000       29,218  
May through October 2015 $605,000 Notes convertible into preferred stock at $1 per share, 8-10% interest, due September 30, 2015     -       17,341       -       17,341  
October through December 2015 $613,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016, net of debt discount of $0 and $0, respectively     -       5,953       -       5,953  
January through March 2016 $345,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016     -       696       -       696  
May 2017 $2,332,305 Notes convertible into common stock after April 15, 2018 at a 45% discount to lowest trade price for previous 30 days ($0.0017 at June 30, 2018), 7.5% interest, due May 2018 therefore in default as of June 30, 2018, net of debt discounts of $0 and $544,845, respectively     2,332,305       200,087       1,833,310       178,304  
May 2017 $530,539 Notes convertible into common stock after April 15, 2018 at a 45% discount to lowest trade price for previous 30 days ($0.0017 at June 30, 2018), 7.5% interest, due May 2018, net of debt discounts of $0 and $147,335, respectively     530,539       58,890       500,703       52,831  
May 2017 $76,379 Notes convertible after April 15, 2018 into common stock at a 45% discount to lowest trade price for previous 30 days ($0.0017 at June 30, 2018), 7.5% interest, due May 2018 therefore in default as of June 30, 2018, net of debt discounts of $0 and $25,085, respectively     76,379       16,724       85,227       15,773  
November 2017 $166,666 Note convertible at maturity at a 50% discount to lowest trade price for previous 25 days ($0.0015 at June 30, 2018), with a one-time interest charge of 10%, due April 15, 2018 therefore in default as of June 30, 2018, net of debt discounts of $0 and $74,662, respectively     166,666       96,667       92,004       16,667  
                                 
Penalties on notes in default     7,918       -       7,028       -  
Total Convertible Notes Payable, Net   $ 3,158,807     $ 428,246     $ 2,563,272     $ 316,784  
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Derivative Liability
 6 Months Ended
Jun. 30, 2018
Notes to Financial Statements  
Derivative Liability

NOTE 6: DERIVATIVE LIABILITY

 

During the six months ended June 30, 2018 the Company had certain convertible notes become convertible on a set date at variable conversion rates. Upon becoming convertible the Company bifurcated the embedded conversion feature and recorded a derivative liability at fair value with the offsetting entry recorded in the statement of operations. The activity in the derivative liability account during the six months ended June 30, 2018 is summarized as follows:

 

Derivative Liability at December 31, 2017   $ -  
Derivative Liability Recorded     4,636,517  
Elimination of Liability on Conversion     (271,851 )
Change in Fair Value     867,608  
Derivative Liability at June 30, 2018   $ 5,232,274  

 

The Company uses the Black-Scholes pricing model to estimate fair value for those instruments convertible into common stock at inception, at conversion date, and at each reporting date.  During the six months ended June 30, 2018 the Company used the following assumptions in their Black-Scholes model:

 

Risk-free interest rate     1.62% - 2.35 %
Expected life in years     0.12 - 1.10  
Dividend yield     0 %
Expected volatility     174.46% - 221.03 %
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Common Stock Options and Warrants
 6 Months Ended
Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Common Stock Options and Warrants

NOTE 7: COMMON STOCK OPTIONS AND WARRANTS

 

Common Stock Options

 

The Company recognizes in the financial statements compensation related to all stock-based awards, including stock options and warrants, based on their estimated grant-date fair value. The Company has estimated expected forfeitures and is recognizing compensation expense only for those awards expected to vest. All compensation is recognized by the time the award vests.

 

The following schedule summarizes the changes in the Company’s stock options:

 

                Weighted           Weighted  
    Options Outstanding     Average           Average  
    Number     Exercise     Remaining     Aggregate     Exercise  
    Of     Price     Contractual     Intrinsic     Price  
    Shares     Per Share     Life     Value     Per Share  
                               
Balance at December 31, 2017     1,222,500     $ 0.50-15       2.91 years     $ -     $ 1.08  
                                         
Options granted     -     $ -       -             $ -  
Options exercised     -     $ -       -             $ -  
Options expired     -     $ -       -             $ -  
                                         
Balance at June 30, 2018     1,222,500     $ 0.50-15       2.42 years     $ -     $ 1.08  
                                         
Exercisable at June 30, 2018     1,222,500     $ 0.50-15       2.42 years     $ -     $ 1.08  

 

During the three and six months ended June 31, 2018 the Company recognized $21,645 and $45,400 worth of stock based compensation related to the vesting of its stock options.

 

Common Stock Warrants

 

The following schedule summarizes the changes in the Company’s stock warrants:

 

          Weighted           Weighted  
    Warrants Outstanding     Average           Average  
    Number     Exercise     Remaining     Aggregate     Exercise  
    Of     Price     Contractual     Intrinsic     Price  
    Shares     Per Share     Life     Value     Per Share  
                               
Balance at December 31, 2017     304,200     $ 0.40-10       1.19 years     $ -     $ 2.63  
                                         
Warrants granted     -     $ -       -             $    
Warrants exercised     -     $ -       -             $    
Warrants expired/cancelled     400     $ -       -             $ 6.00  
                                         
Balance at June 30, 2018     303,800     $ 0.40-10       0.70 years     $ -     $ 2.63  
                                         
Exercisable at June 30, 2018     303,800     $ 0.40-10       0.70 years     $ -     $ 2.63  

 

Restricted Stock Units

 

The following schedule summarizes the changes in the Company’s restricted stock units:

 

          Weighted  
    Number     Average  
    Of     Grant Date  
    Shares     Fair Value  
             
Balance at December 31, 2017     5,740,000     $ 0.07  
                 
RSU’s granted     -     $ -  
RSU’s vested     (1,240,000 )   $ -  
RSU’s forfeited     -     $ -  
                 
Balance at June 30, 2018     4,500,000     $ 0.07  

 

During the three and the six months ended June 30, 2018 the Company recognized $32,801 and $84,895 worth of expense related to the vesting of its RSU’s. As of June 30, 2018, the Company had $269,534 worth of expense yet to be recognized for RSU’s not yet vested.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity
 6 Months Ended
Jun. 30, 2018
Equity [Abstract]  
Stockholders' Equity

NOTE 8: STOCKHOLDERS’ EQUITY

 

Common Stock

 

During the six months ending June 30, 2018 the Company issued 41,146,060 shares of its common stock valued at $376,181 for conversion of convertible debt, 10,000 shares of its common stock valued at $449 for services, 9,666,670 shares of its common stock valued at $3,972,942 for conversions of 966,667 shares of Series A Preferred, and 1,240,000 shares of its common stock valued at $1,240 in the form of Restricted Stock Units.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Supplemental Cash Flow Information
 6 Months Ended
Jun. 30, 2018
Supplemental Cash Flow Elements [Abstract]  
Supplemental Cash Flow Information

NOTE 9: SUPPLEMENTAL CASH FLOW INFORMATION

 

During the six months ending June 30, 2018 the Company had the following non-cash investing and financing activities:

 

  ● Exchanged $32,279 of accounts payable for a one year, 18% Promissory note.
     
  ● Issued 9,666,670 shares of common stock in exchange for 966,667 shares of Series A Preferred decreasing preferred stock by $3,972,942, increasing common stock by $9,667, and increasing paid in capital by $3,963,275.
     
  ● Increased common stock and decreased paid in capital by $1,240 due to the vesting of restricted stock units.
     
  ● Issued 41,146,060 shares of common stock in exchange for convertible note principal of $197,283 and accrued interest of $3,439, reducing the derivative liability by $271,851.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies
 6 Months Ended
Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

NOTE 10: COMMITMENTS AND CONTINGENCIES

 

The Company is continuing work on many avenues to find the money needed to fund operations and provide sufficient funds needed to bring its product to market.  The Company entered into an agreement in May 2018 to find accredited investors for funding the Company under which it will pay a 5% finders fee of the gross proceeds for any financing made available to the Company plus common stock shares equal to 5% of the aggregate proceeds divided by the price per share of common stock issued in connection with the financing.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events
 6 Months Ended
Jun. 30, 2018
Subsequent Events [Abstract]  
Subsequent Events

NOTE 11: SUBSEQUENT EVENTS

 

  ● In July and August 2018, the Company received $13,645 as a loan from a Director.
     
    In July 2018, the Company issued a six month, 8%, convertible promissory note for $50,000.
     
  ● In July and August 2018, the Company issued 255,759,303 shares of common stock in exchange for $418,168 of convertible debt and $17,745 of accrued interest.
     
  ● In July 2018, the Company issued 410,160 shares of common stock for 41,016 shares of Series A Preferred.

 

The Company has evaluated subsequent events through the date of this filing pursuant to ASC Topic 855 and has determined that, except as disclosed herein, there are no additional subsequent events to disclose.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basis of Presentation and Significant Accounting Policies (Policies)
 6 Months Ended
Jun. 30, 2018
Accounting Policies [Abstract]  
Use of Estimates

Use of Estimates

 

The preparation of financial statements in accordance with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

Fair Value of Financial Instruments, requires disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate that value. As of June 30, 2018 and December 31, 2017, the balances reported for cash, prepaid expenses, accounts receivable, accounts payable, and accrued expenses, approximate the fair value because of their short maturities.

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 established a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include:

 

Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;

 

Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and

 

Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.

 

The Company measures certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis were calculated using the Black-Scholes pricing model and are as follows at June 30, 2018:

 

June 30, 2018                        
                         
    Total     Level 1     Level 2     Level 3  
Liabilities:                                
Derivative Liability   $ 5,232,274     $       $       $ 5,232,274  
Total Liabilities Measured at Fair Value   $ 5,232,274     $ -     $ -     $ 5,232,274  
Derivative Liabilities

Derivative Liabilities

 

The Company evaluates its convertible debt, options, warrants or other contracts, if any, to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for in accordance with Accounting Standards Codification topic 815, Accounting for Derivative Instruments and Hedging Activities (“ASC 815”) as well as related interpretations of this standard and Accounting Standards Update 2017-11, which was adopted by the Company effective January 1, 2018. In accordance with this standard, derivative instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair values with gains or losses recognized in earnings. Embedded derivatives that are not clearly and closely related to the host contract are bifurcated and are recognized at fair value with changes in fair value recognized as either a gain or loss in earnings.

 

The result of this accounting treatment is that the fair value of the derivative instrument is marked-to-market each balance sheet date and with the change in fair value recognized in the statement of operations as other income or expense.

 

Upon conversion, exercise or cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise or cancellation and then that the related fair value is removed from the books. Gains or losses on debt extinguishment are recognized in the statement of operations upon conversion, exercise or cancellation of a derivative instrument after any shares issued in such a transaction are recorded at market value. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification are reclassified to liability at the fair value of the instrument on the reclassification date. Instruments that become a derivative after inception are recognized as a derivative on the date they become a derivative with the offsetting entry recorded in earnings.

 

The Company determines the fair value of derivative instruments and hybrid instruments, considering all of the rights and obligations of each instrument, based on available market data using the Black-Scholes model, adjusted for the effect of dilution, because it embodies all of the requisite assumptions (including trading volatility, estimated terms, dilution and risk-free rates) necessary to fair value these instruments. For instruments in default with no remaining time to maturity the Company uses a one-year term for their years to maturity estimate unless a sooner conversion date can be estimated or is known. Estimating fair values of derivative financial instruments requires the development of significant and subjective estimates that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques (such as Black-Scholes model) are highly volatile and sensitive to changes in the trading market price of our common stock.
Reclassifications

Reclassifications

 

Certain account balances from prior periods have been reclassified in the current period financial statements so as to conform to current period classifications.
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

There are no recently issued accounting pronouncements that the Company has not yet adopted that they believe are applicable or would have a material impact on the financial statements of the Company.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basis of Presentation and Significant Accounting Policies (Tables)
 6 Months Ended
Jun. 30, 2018
Accounting Policies [Abstract]  
Schedule of Fair Value of Financial Instruments

The Company measures certain financial instruments at fair value on a recurring basis. Assets and liabilities measured at fair value on a recurring basis were calculated using the Black-Scholes pricing model and are as follows at June 30, 2018:

 

June 30, 2018                        
                         
    Total     Level 1     Level 2     Level 3  
Liabilities:                                
Derivative Liability   $ 5,232,274     $       $       $ 5,232,274  
Total Liabilities Measured at Fair Value   $ 5,232,274     $ -     $ -     $ 5,232,274  
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fixed Assets (Tables)
 6 Months Ended
Jun. 30, 2018
Property, Plant and Equipment [Abstract]  
Schedule of Fixed Assets

Fixed assets consist of the following at June 30, 2018 and December 31, 2017:

 

    June 30,
2018		     December 31,
2017		  
Production equipment   $ 15,182     $ 15,182  
Less accumulated depreciation     (15,182 )     (15,182 )
    $ -     $ -  
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
Convertible Notes Payable (Tables)
 6 Months Ended
Jun. 30, 2018
Debt Disclosure [Abstract]  
Schedule of Convertible Notes Payable

As of June 30, 2018 and December 31, 2017 the Company had the following convertible notes outstanding:

 

    June 30, 2018     December 31, 2017  
   

Principal

(net)

     Accrued Interest    

Principal

(net)

     Accrued Interest  
July and August 2012 $1,060,000 Notes convertible into common stock at $4.60 per share, 12% interest, due December 2013 and January 2014   $ 45,000     $ 31,888     $ 45,000       29,218  
May through October 2015 $605,000 Notes convertible into preferred stock at $1 per share, 8-10% interest, due September 30, 2015     -       17,341       -       17,341  
October through December 2015 $613,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016, net of debt discount of $0 and $0, respectively     -       5,953       -       5,953  
January through March 2016 $345,000 Notes convertible into preferred stock at $1 per share, 8% interest, due June 30, 2016     -       696       -       696  
May 2017 $2,332,305 Notes convertible into common stock after April 15, 2018 at a 45% discount to lowest trade price for previous 30 days ($0.0017 at June 30, 2018), 7.5% interest, due May 2018 therefore in default as of June 30, 2018, net of debt discounts of $0 and $544,845, respectively     2,332,305       200,087       1,833,310       178,304  
May 2017 $530,539 Notes convertible into common stock after April 15, 2018 at a 45% discount to lowest trade price for previous 30 days ($0.0017 at June 30, 2018), 7.5% interest, due May 2018, net of debt discounts of $0 and $147,335, respectively     530,539       58,890       500,703       52,831  
May 2017 $76,379 Notes convertible after April 15, 2018 into common stock at a 45% discount to lowest trade price for previous 30 days ($0.0017 at June 30, 2018), 7.5% interest, due May 2018 therefore in default as of June 30, 2018, net of debt discounts of $0 and $25,085, respectively     76,379       16,724       85,227       15,773  
November 2017 $166,666 Note convertible at maturity at a 50% discount to lowest trade price for previous 25 days ($0.0015 at June 30, 2018), with a one-time interest charge of 10%, due April 15, 2018 therefore in default as of June 30, 2018, net of debt discounts of $0 and $74,662, respectively     166,666       96,667       92,004       16,667  
                                 
Penalties on notes in default     7,918       -       7,028       -  
Total Convertible Notes Payable, Net   $ 3,158,807     $ 428,246     $ 2,563,272     $ 316,784  
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
Derivative Liability (Tables)
 6 Months Ended
Jun. 30, 2018
Notes to Financial Statements  
Schedule of Derivative Liability Account Activity

The activity in the derivative liability account during the six months ended June 30, 2018 is summarized as follows:

 

Derivative Liability at December 31, 2017   $ -  
Derivative Liability Recorded     4,636,517  
Elimination of Liability on Conversion     (271,851 )
Change in Fair Value     867,608  
Derivative Liability at June 30, 2018   $ 5,232,274  
Schedule of Assumptions for Fair Value Determination

During the six months ended June 30, 2018 the Company used the following assumptions in their Black-Scholes model:

 

Risk-free interest rate     1.62% - 2.35 %
Expected life in years     0.12 - 1.10  
Dividend yield     0 %
Expected volatility     174.46% - 221.03 %
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Common Stock Options and Warrants (Tables)
 6 Months Ended
Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of Changes in Stock Option

The following schedule summarizes the changes in the Company’s stock options:

 

                Weighted           Weighted  
    Options Outstanding     Average           Average  
    Number     Exercise     Remaining     Aggregate     Exercise  
    Of     Price     Contractual     Intrinsic     Price  
    Shares     Per Share     Life     Value     Per Share  
                               
Balance at December 31, 2017     1,222,500     $ 0.50-15       2.91 years     $ -     $ 1.08  
                                         
Options granted     -     $ -       -             $ -  
Options exercised     -     $ -       -             $ -  
Options expired     -     $ -       -             $ -  
                                         
Balance at June 30, 2018     1,222,500     $ 0.50-15       2.42 years     $ -     $ 1.08  
                                         
Exercisable at June 30, 2018     1,222,500     $ 0.50-15       2.42 years     $ -     $ 1.08  
Schedule of Changes in Stock Warrants

The following schedule summarizes the changes in the Company’s stock warrants:

 

          Weighted           Weighted  
    Warrants Outstanding     Average           Average  
    Number     Exercise     Remaining     Aggregate     Exercise  
    Of     Price     Contractual     Intrinsic     Price  
    Shares     Per Share     Life     Value     Per Share  
                               
Balance at December 31, 2017     304,200     $ 0.40-10       1.19 years     $ -     $ 2.63  
                                         
Warrants granted     -     $ -       -             $    
Warrants exercised     -     $ -       -             $    
Warrants expired/cancelled     400     $ -       -             $ 6.00  
                                         
Balance at June 30, 2018     303,800     $ 0.40-10       0.70 years     $ -     $ 2.63  
                                         
Exercisable at June 30, 2018     303,800     $ 0.40-10       0.70 years     $ -     $ 2.63  
Schedule of Changes in Restricted Stock Units

The following schedule summarizes the changes in the Company’s restricted stock units:

 

          Weighted  
    Number     Average  
    Of     Grant Date  
    Shares     Fair Value  
             
Balance at December 31, 2017     5,740,000     $ 0.07  
                 
RSU’s granted     -     $ -  
RSU’s vested     (1,240,000 )   $ -  
RSU’s forfeited     -     $ -  
                 
Balance at June 30, 2018     4,500,000     $ 0.07  
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basis of Presentation and Significant Accounting Policies - Schedule of Fair Value of Financial Instruments (Details)
Jun. 30, 2018
USD ($)
Fair Value, Measurements, Recurring [Member]  
Derivative Liability $ 5,232,274
Total Liabilities Measured at Fair Value 5,232,274
Level 1 [Member]  
Derivative Liability
Total Liabilities Measured at Fair Value
Level 2 [Member]  
Derivative Liability
Total Liabilities Measured at Fair Value
Level 3 [Member]  
Derivative Liability 5,232,274
Total Liabilities Measured at Fair Value $ 5,232,274
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Going Concern (Details Narrative) - USD ($)
 6 Months Ended
Jun. 30, 2018
Dec. 31, 2017
Requires funding to maintain current operating activities $ 1,500,000  
Cash on hand $ 8,317
Minimum [Member]    
Capital 5,000,000  
Maximum [Member]    
Capital $ 10,000,000  
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fixed Assets (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Property, Plant and Equipment [Abstract]        
Depreciation expense $ 0 $ 733 $ 1,473
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fixed Assets - Schedule of Fixed Assets (Details) - USD ($)
Jun. 30, 2018
Dec. 31, 2017
Net fixed assets
Production Equipment [Member]    
Production equipment 15,182 15,182
Less accumulated depreciation (15,182) (15,182)
Net fixed assets
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Transactions (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Dec. 31, 2017
Mar. 31, 2017
Accrued interest payable $ 428,246   $ 428,246 $ 316,784  
Related party note 383,771   383,771 383,771  
Related party payables 82,572   $ 82,572 57,297  
Expire Date     Apr. 01, 2017    
Rental expense 0 $ 4,500      
Shareholder and Director [Member]          
Payment of rent     $ 1,500    
Series A Preferred Stock [Member] | CEO [Member]          
Number of shares issued, shares       100,000  
Accrued payroll       32,308  
Accrued payable       67,692  
Wages valued       199,690  
Series A Preferred Stock [Member] | CFO [Member]          
Number of shares issued, shares       83,279  
Accrued payroll       83,280  
Wages valued       166,299  
Related Party Note [Member]          
Accrued interest payable $ 48,261   $ 48,261 $ 29,230  
Director and Major Stockholder [Member]          
Accrued interest payable         $ 51,576
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) - USD ($)
Jun. 30, 2018
Dec. 31, 2017
Principal (net) $ 3,158,807 $ 2,563,272
Accrued Interest 428,246 316,784
Penalties on notes past due principal (net) 7,918 7,028
Convertible Notes Payable One [Member]    
Principal (net) 45,000 45,000
Accrued Interest 31,888 29,218
Convertible Notes Payable Two [Member]    
Principal (net)
Accrued Interest 17,341 17,341
Convertible Notes Payable Three [Member]    
Principal (net)
Accrued Interest 5,953 5,953
Convertible Notes Payable Four [Member]    
Principal (net)
Accrued Interest 696 696
Convertible Notes Payable Five [Member]    
Principal (net) 2,332,305 1,833,310
Accrued Interest 200,087 178,304
Convertible Notes Payable Six [Member]    
Principal (net) 530,539 500,703
Accrued Interest 58,890 52,831
Convertible Notes Payable Seven [Member]    
Principal (net) 76,379 85,227
Accrued Interest 16,724 15,773
Convertible Notes Payable Eight [Member]    
Principal (net) 166,666 92,004
Accrued Interest $ 96,667 $ 16,667
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) (Parenthetical)
 6 Months Ended
Jun. 30, 2018
USD ($)
Number
$ / shares
Dec. 31, 2017
USD ($)
Convertible Notes Payable One [Member]    
Debt principal amount $ 1,060,000  
Debt conversion price per share | $ / shares $ 4.60  
Debt interest rate 12.00%  
Debt maturity date description December 2013 and January 2014  
Convertible Notes Payable Two [Member]    
Debt principal amount $ 605,000  
Debt conversion price per share | $ / shares $ 1  
Debt maturity date description September 30, 2015  
Convertible Notes Payable Two [Member] | Minimum [Member]    
Debt interest rate 8.00%  
Convertible Notes Payable Two [Member] | Maximum [Member]    
Debt interest rate 10.00%  
Convertible Notes Payable Three [Member]    
Debt principal amount $ 613,000  
Debt conversion price per share | $ / shares $ 1  
Debt interest rate 8.00%  
Debt maturity date description June 30, 2016  
Debt discount $ 0 $ 0
Convertible Notes Payable Four [Member]    
Debt principal amount $ 345,000  
Debt conversion price per share | $ / shares $ 1  
Debt interest rate 8.00%  
Debt maturity date description June 30, 2016  
Convertible Notes Payable Five [Member]    
Debt principal amount $ 2,332,305  
Debt conversion price per share | $ / shares $ 0.0017  
Debt interest rate 7.50%  
Debt maturity date description May 2018  
Debt discount $ 0 544,845
Debt instrument trading percentage 45.00%  
Debt trading days | Number 30  
Convertible Notes Payable Six [Member]    
Debt principal amount $ 530,539  
Debt conversion price per share | $ / shares $ 0.0017  
Debt interest rate 7.50%  
Debt maturity date description May 2018  
Debt discount $ 0 147,335
Debt instrument trading percentage 45.00%  
Debt trading days | Number 30  
Convertible Notes Payable Seven [Member]    
Debt principal amount $ 76,379  
Debt conversion price per share | $ / shares $ 0.0017  
Debt interest rate 7.50%  
Debt maturity date description May 2018  
Debt discount $ 0 25,085
Debt instrument trading percentage 45.00%  
Debt trading days | Number 30  
Convertible Notes Payable Eight [Member]    
Debt principal amount $ 166,666  
Debt conversion price per share | $ / shares $ 0.0015  
Debt interest rate 10.00%  
Debt maturity date description April 15, 2018  
Debt discount $ 0 $ 74,662
Debt instrument trading percentage 50.00%  
Debt trading days | Number 25  
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Derivative Liability - Schedule of Derivative Liability Account Activity (Details)
 6 Months Ended
Jun. 30, 2018
USD ($)
Notes to Financial Statements  
Derivative Liability, Beginning balance
Derivative Liability Recorded 4,636,517
Elimination of Liability on Conversion (271,851)
Change in Fair Value 867,608
Derivative Liability, Ending balance $ 5,232,274
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Derivative Liability - Schedule of Assumptions for Fair Value Determination (Details)
 6 Months Ended
Jun. 30, 2018
Risk-free Interest Rate [Member] | Minimum [Member]  
Fair value assumptions, percentage 1.62%
Risk-free Interest Rate [Member] | Maximum [Member]  
Fair value assumptions, percentage 2.35%
Expected Term [Member] | Minimum [Member]  
Fair value assumption, expected term 1 month 13 days
Expected Term [Member] | Maximum [Member]  
Fair value assumption, expected term 1 year 1 month 6 days
Dividend Yield [Member]  
Fair value assumptions, percentage 0.00%
Expected Volatility [Member] | Minimum [Member]  
Fair value assumptions, percentage 174.46%
Expected Volatility [Member] | Maximum [Member]  
Fair value assumptions, percentage 221.03%
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
Common Stock Options and Warrants (Details Narrative)
 3 Months Ended 6 Months Ended
Jun. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Common Stock Option [Member]    
Stock based compensation $ 21,645 $ 45,400
Restricted Stock Units [Member]    
Restricted stock expense 32,801 84,895
Stock options expense yet to be recognized $ 269,534 $ 269,534
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Common Stock Options and Warrants - Schedule of Changes in Stock Option (Details) - Stock Options
 6 Months Ended
Jun. 30, 2018
USD ($)
$ / shares
shares
Number of Shares Options Outstanding Beginning Balance | shares 1,222,500
Number of Options granted | shares
Number of Options exercised | shares
Number of Options expired | shares
Number of Shares Options Outstanding Ending Balance | shares 1,222,500
Number of Shares Options Exercisable | shares 1,222,500
Weighted Average Exercise Price granted
Weighted Average Exercise Price exercised
Weighted Average Exercise Price expired
Weighted Average Remaining Contractual Life (in years) Outstanding, Beginning 2 years 10 months 28 days
Weighted Average Remaining Contractual Life (in years) Outstanding, Ending 2 years 5 months 1 day
Weighted Average Remaining Contractual Life (in years) Exercisable 2 years 5 months 1 day
Aggregate Intrinsic Value Outstanding Beginning | $
Aggregate Intrinsic Value Outstanding Ending | $
Aggregate Intrinsic Value Exercisable | $
Weighted Average Exercise Price Per Share Outstanding Beginning $ 1.08
Weighted Average Exercise Price Per Share Options granted
Weighted Average Exercise Price Per Share Options exercised
Weighted Average Exercise Price Per Share Options expired
Weighted Average Exercise Price Per Share Outstanding Ending 1.08
Weighted Average Exercise Price Per Share Exercisable 1.08
Minimum [Member]  
Weighted Average Exercise Price Outstanding Beginning Balance 0.50
Weighted Average Exercise Price granted
Weighted Average Exercise Price exercised
Weighted Average Exercise Price expired
Weighted Average Exercise Price Outstanding Ending Balance 0.50
Exercise Price Per Share Exercisable 0.50
Maximum [Member]  
Weighted Average Exercise Price Outstanding Beginning Balance 15
Weighted Average Exercise Price granted
Weighted Average Exercise Price exercised
Weighted Average Exercise Price expired
Weighted Average Exercise Price Outstanding Ending Balance 15
Exercise Price Per Share Exercisable $ 15
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
Common Stock Options and Warrants - Schedule of Changes in Stock Warrants (Details) - Warrants [Member]
 6 Months Ended
Jun. 30, 2018
USD ($)
$ / shares
shares
Number of Shares, Warrants Outstanding Beginning | shares 304,200
Number of Shares, Warrants granted | shares
Number of Shares, Warrants exercised | shares
Number of Shares, Warrants expired/cancelled | shares 400
Number of Shares, Warrants Outstanding Ending | shares 303,800
Number of Shares, Warrants Exercisable Ending | shares 303,800
Exercise Price Per Share Warrants granted
Exercise Price Per Share Warrants exercised
Exercise Price Per Share Warrants expired/cancelled
Weighted Average Remaining Contractual Life Warrants Outstanding, Beginning 1 year 2 months 8 days
Weighted Average Remaining Contractual Life Warrants Outstanding Ending 8 months 12 days
Weighted Average Remaining Contractual Life Warrants Exercisable 8 months 12 days
Aggregate Intrinsic Value Outstanding Beginning | $
Aggregate Intrinsic Value Outstanding Ending | $
Aggregate Intrinsic Value Exercisable | $
Weighted Average Exercise Price Per Share Exercise Price Warrants Beginning $ 2.63
Weighted Average Exercise Price Per Share Exercise Price Warrants granted
Weighted Average Exercise Price Per Share Exercise Price Warrants exercised
Weighted Average Exercise Price Per Share Exercise Price Warrants expired/cancelled 6.00
Weighted Average Exercise Price Per Share Exercise Price Warrants Ending 2.63
Weighted Average Exercise Price Per Share Exercise Price Warrants Exercisable 2.63
Minimum [Member]  
Weighted Average Exercise Price Outstanding 0.40
Exercise Price Per Share Warrants granted
Exercise Price Per Share Warrants exercised
Exercise Price Per Share Warrants expired/cancelled
Weighted Average Exercise Price Outstanding 0.40
Exercise Price Per Share Exercisable 0.40
Maximum [Member]  
Weighted Average Exercise Price Outstanding 10
Exercise Price Per Share Warrants granted
Exercise Price Per Share Warrants exercised
Exercise Price Per Share Warrants expired/cancelled
Weighted Average Exercise Price Outstanding 10
Exercise Price Per Share Exercisable $ 10
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1
Common Stock Options and Warrants - Schedule of Changes in Restricted Stock Units (Details) - Restricted Stock Units [Member]
 6 Months Ended
Jun. 30, 2018
$ / shares
shares
Number of Shares, RSU's Outstanding Beginning | shares 5,740,000
Number of Shares, RSU's Granted | shares
Number of Shares, RSU's Vested | shares (1,240,000)
Number of Shares, RSU's Forfeited | shares
Number of Shares, RSU's Outstanding Ending | shares 4,500,000
Weighted Average Grant Date Fair Value, RSU's Outstanding Beginning | $ / shares $ 0.07
Weighted Average Grant Date Fair Value, RSU's Granted | $ / shares
Weighted Average Grant Date Fair Value, RSU's Vested | $ / shares
Weighted Average Grant Date Fair Value, RSU's Forfeited | $ / shares
Weighted Average Grant Date Fair Value, RSU's Outstanding Ending | $ / shares $ 0.07
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' Equity (Details Narrative)
 6 Months Ended
Jun. 30, 2018
USD ($)
shares
Number of shares issued for conversion of convertible debt 41,146,060
Number of shares issued for conversion of convertible debt, amount | $ $ 376,181
Restricted Stock Units [Member]  
Number of stock issued during period 1,240,000
Value of stock issued during period | $ $ 1,240
Common Stock [Member]  
Common stock issued for services 10,000
Common stock issued for services, value | $ $ 449
Number of common shares issued for conversion of preferred stock 9,666,670
Series A Preferred Stock [Member]  
Number of common shares issued for conversion of preferred stock 966,667
Number of common shares issued for conversion of preferred stock, value | $ $ 3,972,942
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1
Supplemental Cash Flow Information (Details Narrative)
 6 Months Ended
Jun. 30, 2018
USD ($)
shares
Issued shares of common stock in exchange for preferred stock | shares 9,666,670
Decrease in preferred stock $ 3,972,942
Increase in common stock 9,667
Increase in additional paid in capital $ 3,963,275
Number of shares issued to exchange convertible note principal | shares 41,146,060
Convertible notes payable $ 197,283
Accrued interest 3,439
Reducing derivative liability 271,851
Restricted Stock Units [Member]  
Increased common stock and decreased in capital $ 1,240
Series A Preferred Stock [Member]  
Number of shares exchanged | shares 966,667
Promissory Note [Member]  
Exchanged accounts payable $ 32,279
Debt interest rate 18.00%
Debt maturity date description Accounts payable for a one year
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies (Details Narrative)
 6 Months Ended
Jun. 30, 2018
Employee [Member]  
Investors funding, description The Company under which it will pay a 5% finders fee of the gross proceeds for any financing made available to the Company plus common stock shares equal to 5% of the aggregate proceeds divided by the price per share of common stock issued in connection with the financing.
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events (Details Narrative) - USD ($)
 1 Months Ended 6 Months Ended
Aug. 31, 2018
Jul. 31, 2018
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Proceeds from loan     $ 38,559  
Convertible promissory note     $ 197,283    
Common stock issued for conversion of debt, shares     41,146,060    
Debt conversion of convertible debt     $ 376,181    
Accrued interest     $ 428,246   $ 316,784
Series A Preferred Stock [Member]          
Conversion of stock, shares     966,667    
Conversion of stock, number of shares converted     966,667    
Subsequent Event [Member]          
Common stock issued for conversion of debt, shares 255,759,303 255,759,303      
Debt conversion of convertible debt $ 418,168 $ 418,168      
Accrued interest $ 17,745 $ 17,745      
Subsequent Event [Member] | Series A Preferred Stock [Member]          
Conversion of stock, number of shares converted   41,016      
Subsequent Event [Member] | 8% Convertible Promissory Note [Member]          
Convertible promissory note   $ 50,000      
EXCEL 50 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 52 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 54 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 93 209 1 false 34 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://isotopeworld.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets Sheet http://isotopeworld.com/role/BalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://isotopeworld.com/role/BalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://isotopeworld.com/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statements of Cash Flow (Unaudited) Sheet http://isotopeworld.com/role/StatementsOfCashFlow Condensed Statements of Cash Flow (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - Basis of Presentation and Significant Accounting Policies Sheet http://isotopeworld.com/role/BasisOfPresentationAndSignificantAccountingPolicies Basis of Presentation and Significant Accounting Policies Notes 6 false false R7.htm 00000007 - Disclosure - Going Concern Sheet http://isotopeworld.com/role/GoingConcern Going Concern Notes 7 false false R8.htm 00000008 - Disclosure - Fixed Assets Sheet http://isotopeworld.com/role/FixedAssets Fixed Assets Notes 8 false false R9.htm 00000009 - Disclosure - Related Party Transactions Sheet http://isotopeworld.com/role/RelatedPartyTransactions Related Party Transactions Notes 9 false false R10.htm 00000010 - Disclosure - Convertible Notes Payable Notes http://isotopeworld.com/role/ConvertibleNotesPayable Convertible Notes Payable Notes 10 false false R11.htm 00000011 - Disclosure - Derivative Liability Sheet http://isotopeworld.com/role/DerivativeLiability Derivative Liability Notes 11 false false R12.htm 00000012 - Disclosure - Common Stock Options and Warrants Sheet http://isotopeworld.com/role/CommonStockOptionsAndWarrants Common Stock Options and Warrants Notes 12 false false R13.htm 00000013 - Disclosure - Stockholders' Equity Sheet http://isotopeworld.com/role/StockholdersEquity Stockholders' Equity Notes 13 false false R14.htm 00000014 - Disclosure - Supplemental Cash Flow Information Sheet http://isotopeworld.com/role/SupplementalCashFlowInformation Supplemental Cash Flow Information Notes 14 false false R15.htm 00000015 - Disclosure - Commitments and Contingencies Sheet http://isotopeworld.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 00000016 - Disclosure - Subsequent Events Sheet http://isotopeworld.com/role/SubsequentEvents Subsequent Events Notes 16 false false R17.htm 00000017 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies) Sheet http://isotopeworld.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies Basis of Presentation and Significant Accounting Policies (Policies) Policies http://isotopeworld.com/role/BasisOfPresentationAndSignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables) Sheet http://isotopeworld.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables Basis of Presentation and Significant Accounting Policies (Tables) Tables http://isotopeworld.com/role/BasisOfPresentationAndSignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - Fixed Assets (Tables) Sheet http://isotopeworld.com/role/FixedAssetsTables Fixed Assets (Tables) Tables http://isotopeworld.com/role/FixedAssets 19 false false R20.htm 00000020 - Disclosure - Convertible Notes Payable (Tables) Notes http://isotopeworld.com/role/ConvertibleNotesPayableTables Convertible Notes Payable (Tables) Tables http://isotopeworld.com/role/ConvertibleNotesPayable 20 false false R21.htm 00000021 - Disclosure - Derivative Liability (Tables) Sheet http://isotopeworld.com/role/DerivativeLiabilityTables Derivative Liability (Tables) Tables http://isotopeworld.com/role/DerivativeLiability 21 false false R22.htm 00000022 - Disclosure - Common Stock Options and Warrants (Tables) Sheet http://isotopeworld.com/role/CommonStockOptionsAndWarrantsTables Common Stock Options and Warrants (Tables) Tables http://isotopeworld.com/role/CommonStockOptionsAndWarrants 22 false false R23.htm 00000023 - Disclosure - Basis of Presentation and Significant Accounting Policies - Schedule of Fair Value of Financial Instruments (Details) Sheet http://isotopeworld.com/role/BasisOfPresentationAndSignificantAccountingPolicies-ScheduleOfFairValueOfFinancialInstrumentsDetails Basis of Presentation and Significant Accounting Policies - Schedule of Fair Value of Financial Instruments (Details) Details 23 false false R24.htm 00000024 - Disclosure - Going Concern (Details Narrative) Sheet http://isotopeworld.com/role/GoingConcernDetailsNarrative Going Concern (Details Narrative) Details http://isotopeworld.com/role/GoingConcern 24 false false R25.htm 00000025 - Disclosure - Fixed Assets (Details Narrative) Sheet http://isotopeworld.com/role/FixedAssetsDetailsNarrative Fixed Assets (Details Narrative) Details http://isotopeworld.com/role/FixedAssetsTables 25 false false R26.htm 00000026 - Disclosure - Fixed Assets - Schedule of Fixed Assets (Details) Sheet http://isotopeworld.com/role/FixedAssets-ScheduleOfFixedAssetsDetails Fixed Assets - Schedule of Fixed Assets (Details) Details 26 false false R27.htm 00000027 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://isotopeworld.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://isotopeworld.com/role/RelatedPartyTransactions 27 false false R28.htm 00000028 - Disclosure - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) Notes http://isotopeworld.com/role/ConvertibleNotesPayable-ScheduleOfConvertibleNotesPayableDetails Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) Details 28 false false R29.htm 00000029 - Disclosure - Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) (Parenthetical) Notes http://isotopeworld.com/role/ConvertibleNotesPayable-ScheduleOfConvertibleNotesPayableDetailsParenthetical Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) (Parenthetical) Details 29 false false R30.htm 00000030 - Disclosure - Derivative Liability - Schedule of Derivative Liability Account Activity (Details) Sheet http://isotopeworld.com/role/DerivativeLiability-ScheduleOfDerivativeLiabilityAccountActivityDetails Derivative Liability - Schedule of Derivative Liability Account Activity (Details) Details 30 false false R31.htm 00000031 - Disclosure - Derivative Liability - Schedule of Assumptions for Fair Value Determination (Details) Sheet http://isotopeworld.com/role/DerivativeLiability-ScheduleOfAssumptionsForFairValueDeterminationDetails Derivative Liability - Schedule of Assumptions for Fair Value Determination (Details) Details 31 false false R32.htm 00000032 - Disclosure - Common Stock Options and Warrants (Details Narrative) Sheet http://isotopeworld.com/role/CommonStockOptionsAndWarrantsDetailsNarrative Common Stock Options and Warrants (Details Narrative) Details http://isotopeworld.com/role/CommonStockOptionsAndWarrantsTables 32 false false R33.htm 00000033 - Disclosure - Common Stock Options and Warrants - Schedule of Changes in Stock Option (Details) Sheet http://isotopeworld.com/role/CommonStockOptionsAndWarrants-ScheduleOfChangesInStockOptionDetails Common Stock Options and Warrants - Schedule of Changes in Stock Option (Details) Details 33 false false R34.htm 00000034 - Disclosure - Common Stock Options and Warrants - Schedule of Changes in Stock Warrants (Details) Sheet http://isotopeworld.com/role/CommonStockOptionsAndWarrants-ScheduleOfChangesInStockWarrantsDetails Common Stock Options and Warrants - Schedule of Changes in Stock Warrants (Details) Details 34 false false R35.htm 00000035 - Disclosure - Common Stock Options and Warrants - Schedule of Changes in Restricted Stock Units (Details) Sheet http://isotopeworld.com/role/CommonStockOptionsAndWarrants-ScheduleOfChangesInRestrictedStockUnitsDetails Common Stock Options and Warrants - Schedule of Changes in Restricted Stock Units (Details) Details 35 false false R36.htm 00000036 - Disclosure - Stockholders' Equity (Details Narrative) Sheet http://isotopeworld.com/role/StockholdersEquityDetailsNarrative Stockholders' Equity (Details Narrative) Details http://isotopeworld.com/role/StockholdersEquity 36 false false R37.htm 00000037 - Disclosure - Supplemental Cash Flow Information (Details Narrative) Sheet http://isotopeworld.com/role/SupplementalCashFlowInformationDetailsNarrative Supplemental Cash Flow Information (Details Narrative) Details http://isotopeworld.com/role/SupplementalCashFlowInformation 37 false false R38.htm 00000038 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://isotopeworld.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://isotopeworld.com/role/CommitmentsAndContingencies 38 false false R39.htm 00000039 - Disclosure - Subsequent Events (Details Narrative) Sheet http://isotopeworld.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://isotopeworld.com/role/SubsequentEvents 39 false false All Reports Book All Reports rdgl-20180630.xml rdgl-20180630.xsd rdgl-20180630_cal.xml rdgl-20180630_def.xml rdgl-20180630_lab.xml rdgl-20180630_pre.xml http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/srt/2018-01-31 true true ZIP 56 0001493152-18-012269-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-18-012269-xbrl.zip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end